var title_f8_26_8608="Cutting foreskin off Mogan clam";
var content_f8_26_8608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Foreskin cut from surface of clamp using a scalpel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8608=[""].join("\n");
var outline_f8_26_8608=null;
var title_f8_26_8609="Roseola rash PI";
var content_f8_26_8609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F76269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F76269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Roseola rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The roseola rash starts as the fever goes away. It shows up first on the neck, chest, and belly and then spreads to the arms, legs, and face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Brady, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8609=[""].join("\n");
var outline_f8_26_8609=null;
var title_f8_26_8610="Contents: Dialysis";
var content_f8_26_8610=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Dialysis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Dialysis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute renal failure and dialysis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/26/9642\">",
"           Acute hemodialysis prescription",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/58/25513\">",
"           Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/25/33174\">",
"           Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4696\">",
"           Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12169\">",
"           Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anemia and chronic renal failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/21/6486\">",
"           Anemia and left ventricular hypertrophy in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/18/41257\">",
"           Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/21/23896\">",
"           Darbepoetin alfa for the management of anemia in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/22/28005\">",
"           Diagnosis of iron deficiency in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/45/33496\">",
"           Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/31/5626\">",
"           Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/3/15412\">",
"           Erythropoietin: Subcutaneous administration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/15/8436\">",
"           Hypertension following erythropoietin in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/55/37752\">",
"           Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/8/9353\">",
"           Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/4/8265\">",
"           Pure red cell aplasia due to anti-erythropoietin antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/39/38521\">",
"           Use of iron preparations in hemodialysis patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cardiac disease and hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/49/33559\">",
"           Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11288\">",
"           Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/15/8436\">",
"           Hypertension following erythropoietin in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/46/20202\">",
"           Hypertension in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/37/24154\">",
"           Inflammation in renal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/61/26584\">",
"           Myocardial dysfunction in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/24/6533\">",
"           Pericarditis in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/0/29703\">",
"           Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/34/554\">",
"           Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/27/11701\">",
"           Serum cardiac enzymes in patients with renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/12/9416\">",
"           Therapy of heart failure in hemodialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/36/15945\">",
"           Treatment and prevention of sudden cardiac arrest in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/22/26984\">",
"           Treatment of coronary heart disease in end-stage renal disease (dialysis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/59/954\">",
"           Valvular heart disease in patients with end-stage renal disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications during dialysis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/9/8343\">",
"           Acute complications during hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24690\">",
"           Cool temperature hemodialysis: Hemodynamic effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/52/13125\">",
"           Dialysis disequilibrium syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/32/31240\">",
"           Hemodynamic instability during hemodialysis: Overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/30/36325\">",
"           Muscle cramps in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/58/22440\">",
"           Seizures in patients undergoing hemodialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dialysis adequacy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/58/1962\">",
"           Adequacy of peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/14/6378\">",
"           Kt/V and the adequacy of hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/13/37082\">",
"           Patient survival and maintenance dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/7/1144\">",
"           Prescribed versus delivered dialysis: Importance of dialysis time",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/17/277\">",
"           Protein catabolic rate in maintenance dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36215\">",
"           Rapid transporters on maintenance peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/38/36456\">",
"           Urine output and residual renal function in renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/15/26868\">",
"           Why Kt/V and creatinine clearance may not correlate in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Dialysis modalities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/39/30330\">",
"           Alternative renal replacement therapies in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31286\">",
"           Choosing a modality for chronic peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/32/34312\">",
"           Dialysis modality and patient outcome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/44/19144\">",
"           Home hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25286\">",
"           Organization and elements of a home hemodialysis program",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/45/18137\">",
"           Short daily hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27940\">",
"           Short daily home hemodialysis: The low dialysate volume approach",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/16/264\">",
"           Technical aspects of nocturnal hemodialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine dysfunction",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/14/19684\">",
"           Autonomic dysfunction in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/43/18102\">",
"           Carbohydrate and insulin metabolism in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/55/14200\">",
"           Carnitine metabolism in renal disease and dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16211\">",
"           Cortisol metabolism in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10614\">",
"           Dialysis in diabetic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/6/17509\">",
"           Growth hormone metabolism in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9273\">",
"           Indications for parathyroidectomy in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7865\">",
"           Management of hyperglycemia in diabetics with end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/58/32681\">",
"           Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38474\">",
"           Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/50/18218\">",
"           Pathogenesis of renal osteodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36484\">",
"           Reproductive and sexual dysfunction in uremic women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/29/20951\">",
"           Sexual dysfunction in uremic men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2453\">",
"           Thyroid function in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33690\">",
"           Treatment of hyperphosphatemia in chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General hemodialysis topics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/43/9911\">",
"           Biochemical mechanisms involved in blood-hemodialysis membrane interactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/17/26902\">",
"           Clinical consequences of hemodialysis membrane biocompatibility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/49/14101\">",
"           Complications of hemodialysis in the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/32/29190\">",
"           Contaminants in water used for hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/31/29174\">",
"           Hemodialysis in the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/33/10775\">",
"           Maintaining water quality for hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/7/115\">",
"           Overview of the hemodialysis apparatus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/33/28179\">",
"           Plasmapheresis with hemodialysis equipment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/3/11322\">",
"           Psychiatric illness in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4295\">",
"           Reactions to the hemodialysis membrane",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/59/7096\">",
"           Reuse of dialyzers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33381\">",
"           Serum enzymes in patients with renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/19/3383\">",
"           Ultrapure dialysate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/51/42805\">",
"           Water purification systems in hemodialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General peritoneal dialysis topics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/6/41061\">",
"           Abdominal hernias in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/58/1962\">",
"           Adequacy of peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/43/24245\">",
"           Bloody peritoneal dialysate (hemoperitoneum)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/39/15991\">",
"           Evaluation of hypervolemia in peritoneal dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/63/33784\">",
"           Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17594\">",
"           Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41477\">",
"           Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/23/22904\">",
"           Noninfectious complications of continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/22/7528\">",
"           Noninfectious complications of peritoneal dialysis catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26248\">",
"           Pathophysiology and prevention of peritonitis in peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/12/18632\">",
"           Peritoneal dialysis solutions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/31/5623\">",
"           Peritoneal equilibration test",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6136\">",
"           Placement and maintenance of the peritoneal dialysis catheter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/50/23337\">",
"           Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36215\">",
"           Rapid transporters on maintenance peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/60/3018\">",
"           Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12169\">",
"           Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection and dialysis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22617\">",
"           Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1048\">",
"           Diagnosis of hepatitis C virus infection in patients on dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8631\">",
"           Fungal peritonitis in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/5/40024\">",
"           Hepatitis B virus and dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/24/31114\">",
"           Hepatitis C virus infection in patients on maintenance dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34344\">",
"           Human immunodeficiency virus and dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/7/35959\">",
"           Immunizations in patients with end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17594\">",
"           Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/61/37849\">",
"           Non-access related infections in chronic dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/40/26248\">",
"           Pathophysiology and prevention of peritonitis in peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29834\">",
"           Tunneled, cuffed hemodialysis catheter-related bacteremia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intoxications",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/16/27909\">",
"           Drug removal during continuous renal replacement therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/4/26695\">",
"           Enhanced elimination of poisons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1129\">",
"           General approach to drug poisoning in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/60/20423\">",
"           Isopropyl alcohol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/43/4792\">",
"           Meprobamate poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/3/4154\">",
"           Methanol and ethylene glycol poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11991\">",
"           Paraquat poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/28/19913\">",
"           Salicylate (aspirin) poisoning in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/16/13578\">",
"           Theophylline poisoning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/38/28264\">",
"           Valproic acid poisoning",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/2/15399\">",
"           Assessment of nutritional status in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/51/33591\">",
"           Leptin and end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14519\">",
"           Nutritional status and protein intake in continuous peritoneal dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9274\">",
"           Pathogenesis and treatment of malnutrition in maintenance dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/17/277\">",
"           Protein catabolic rate in maintenance dialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/14/5352\">",
"           Aluminum toxicity in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/42/15017\">",
"           Calciphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/28/11719\">",
"           Cancer screening in patients with end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/49/14101\">",
"           Complications of hemodialysis in the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/30/5609\">",
"           Dialysis-related amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/50/16165\">",
"           Ethical issues in the care of the patient with end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/16/8456\">",
"           Eye disorders associated with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/31/20986\">",
"           Gastrointestinal disease in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/31/29174\">",
"           Hemodialysis in the elderly patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/52/32581\">",
"           Hemoperfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/32/4616\">",
"           Indications for initiation of dialysis in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/16/37128\">",
"           Lower extremity peripheral artery disease in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/47/36601\">",
"           Medical management of the dialysis patient undergoing surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31082\">",
"           Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/53/36694\">",
"           Palliative care: End-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/30/10727\">",
"           Platelet dysfunction in uremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/25/44437\">",
"           The nephrologist as primary care physician in patients with end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2643\">",
"           Uremic mononeuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/27/14773\">",
"           Uremic polyneuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6937\">",
"           Uremic pruritus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/24/37258\">",
"           Uremic toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/56/8072\">",
"           Withdrawal from and withholding of dialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Slow continuous therapies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/27/37303\">",
"           Continuous arteriovenous hemodialysis: Technical considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/39/38516\">",
"           Continuous renal replacement therapies: Overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/40/28295\">",
"           Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41751\">",
"           Continuous venovenous hemodiafiltration: Technical considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20935\">",
"           Continuous venovenous hemodialysis: Technical considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/16/27909\">",
"           Drug removal during continuous renal replacement therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/24/3465\">",
"           Outcomes associated with nocturnal hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/47/33530\">",
"           Sustained low efficiency or extended daily dialysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular access",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/15/3318\">",
"           Arteriovenous fistula recirculation in hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/16/23816\">",
"           Arteriovenous fistulas and grafts for chronic hemodialysis access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39432\">",
"           Central vein stenosis associated with dialysis access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/21/37210\">",
"           Creating an arteriovenous fistula for hemodialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/5/12376\">",
"           Early and late hemodialysis arteriovenous fistula failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/12/37063\">",
"           Heart failure and hemodialysis arteriovenous fistulae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/14/38120\">",
"           Hemodialysis anticoagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/50/27429\">",
"           Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/38/615\">",
"           Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/15/12536\">",
"           Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/3/16442\">",
"           Overview of central catheters for acute and chronic hemodialysis access",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/21/16727\">",
"           Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/37/18010\">",
"           Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/30/41443\">",
"           Physical examination of the hemodialysis arteriovenous fistula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/38/42594\">",
"           Secondary hemodialysis arteriovenous fistula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/48/7942\">",
"           Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/22/15722\">",
"           Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/42/11944\">",
"           Use of stents for venous stenosis associated with dialysis vascular access",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-A837513504-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_26_8610=[""].join("\n");
var outline_f8_26_8610=null;
var title_f8_26_8611="Difficult airway algorithm";
var content_f8_26_8611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58510%7EEM%2F63518%7EEM%2F73509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58510%7EEM%2F63518%7EEM%2F73509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The difficult airway algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 361px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BMV: bag-mask ventilation; EGD: extra-glottic device; DL: direct laryngoscopy; FO: fiberoptic method; VL: video laryngoscopy; RSI: rapid sequence intubation; ILMA: intubating laryngeal mask; BNTI: blind nasotracheal intubation.",
"     <br/>",
"     * RSI may require a double set-up. See text for details.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If not used for awake laryngoscopy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management,&nbsp;4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Main emergency airway management algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 522px; background-image: url(data:image/gif;base64,R0lGODlhAQIKAtUAAP///+fo6QAAAIiIiLu7u6mqq0RERCIiIpmZmXt8fN3d3R8fH2ZmZjMzMz4+PhEREe7u7szMzFxdXYuLjNjZ2S4uL1VVVQ8PEMjJyrm6und3d01NTqqqqj8/P5qbm2xsbQ8PD8/Pz5+fn6+vr+/v79/f329vb7+/v09PT19fX39/fwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAABAgoCAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpX8CqKmqq6ytrq+wsbKzq6a2t7hDAp67ub6/n72cwsDFxpTEmsnHzM2Jy5jQztPUftKW19Xa23PZUgYDXQIEYd7c5+hoyQYC4QrjUOBJAwZHBNfwSfIA+U/m6QADell3QICCd+Se7INyL0m/Iwul/BNIsSKVdQwMGEAIwAKqBhA6fgzpEdWACA1QWSBCD4CBlAIYACgo4EBGIQcQ8IOpk0Eq/wQIfsJjJ8BASAE8i0y0yLSpEoz3BowbABJAgwFUQ14dcECBS6wNjrTUCOCegoYAbs7U2Q7AgAdEGITdN/UABAhX+YXjqtSp37/+ihiQWZKAz1QMDqNKLPOrAo8NdA4Z684gWrU5+ZEz+xbVga9CxiUWMkAmPASfiSwFzLoiRgDvplYlPdutXQgHwpFOTbqevHdnBYTkS+ABW3IaugrgACC5Sw2hCXC9m1szANR9W2vX/jotvJICdIJHgFfAg9xSUUnuDRp4+a4FGxjn55kc0QOfg4YfisqodeyqbScgYKs5UuCACDpzICMLJuggMA0qEuGDFNoyISIXVqhhKBka0v/hhiBu8iEhI4ZoYiUlCpLiiSw+siIgL7Yo4zO01GjjjTjWOOOOFMbI4487+gjkkCcKSeSRGhqJ5JIJKsnkk9xBKaWUTk5ppUVVXqklQFlu6eU2XX4ppoJjlglimGamaUoIKJzADwAnoBCCmnQCtoAAd+ZZ555OibCKCHwGWhEJIKQCAgmCJhqQCamYoOij6JSQSgmQVrpNBwJ0YOmm1IwgwAichtqMpqKWauqpqKaqqoc5turqq7CsKmt2maA565O2wpHrrUju6oavvA4JLBvDBstjsWoga6yMyqqzrKrXoJVWY2xIqwRNtRnR7LMmRivMaH7gptsR23J7ZhLSjob/lHpugWNQSSChpNJO7KbXQAQuwSQTAg+Y1FB1EDzAAQE0rbeWQ+ae6u0Q6u71GVfkZGUVWKrt9UAEAuB7E1lmGQCdEA3xxdd8HMB1XQPUkpuwqQsLYQF0pz1cj3eIPYbUcWWFlxrB7VmWkgERNBQwAZHFlopX4CK8sqjXQNBWBPPF3C5tIRXBFzzJYYyvBb5V5pXLDFx2wAMhzRdFuUs/mA2/qHwsdUsu/5ReePTVFPFH+P5m0H1B9/KObgR7JkTSSKCddpNnPPTr4ZxmqXgbhjMuYORiUC55a5aDkfnlf/kKtz8JWbE5504tdY9dac1sxedPJfQQtlU3MTrpTJle/5NMaq2ueuvRGSFuYLQnantQhtUTON00HYCvzinPbXzBM3kWgWLvJDVEZk7MHjxFtitggE31kGwyTjCvRATGEYevU8lEHACz6w4LgQDKUGi/fUDdY1yU0ahMj5h1RAAQPfiXMcWYxnXkABDhZHe/QHXPO+obQlC0csAiaK0jEZSfcKxiGub8hzcSaSCfHviO53lGATCxCQDj8hET1gSFnsEdKjiiwJQxUIR1sp8WdIhDMImoh3TiIRaECMRpEFF0RUzTEauwxCQao4lTgKITfyHFs01xTFWs3xXFBKsuetFVW5RcFsP4qDGSUXhnTCMT1chGK7bxjUwwIxyVOMc6qv/Mjg78oh73yEc94tGHnfsjJxrwselchEBL6N915DhHrSlAYGsM5FPws0hBLoIqFljJ8XSigVTgS2l+8UY7HjCAoMAGJh+z5CDGVrb1wWU5NwxlIhEgFal0ZCVQC50qAdESAiqAKzGJ3R1l+RTy0ORgLjHYLv0AN7MVwZnDLN0sF7mLTAIAfcsMBNyOZ5d+IUWY2kJkMXGyCxgKIJXZvAQj8bDOdH6hnXaApzu5IE861HOeWbinHPSJTymwyU27iNOcBPLPNwm0n6XIE57wZBGF6gmhpPCTKgBVEYmmgqIQFQWhDIWoQRUKFYfKKCkYhQpHMYWkAjCpSEUhKVRQiin/LRXAS1cqCkyRqik2pSkpPAUqp/BUp6S4qVOECtSiGvWoSeyjUpc6CzMw9alfLKoAAkDVqlr1qljNqla3ytWuevWrX60SP3UhVbCa9axoTataryrWHwJ1qmuNq1znita2KqOsdM2rXvcaALvWCq98DaxgzerXaAB2sHMVQAEQG1ancoF18RiXW2ZYEMnyLpGHpWoGHJAKCVCAq4pFbGjDuli+FpYI9/jI15hAGSNERDDhGIfTkGO8f4zDWuF861UpcIENULUAFcAAaEsr2NEyFrSOtYdBXGI+1u4OtvoYF8ZcZtlEEgC3tKIpXKuagAVgFQMVQMUHrCqBVGAgAaio/0AGrApeVGygAIoVwARSUQEKZCC8AvCtAPA7gaveCU/rVSx84ZuAC1g1AwKgwH8XkIEJXOCzCagAW5NrBLPY5h73oKX0Jtsf0MxtbgYDT2yPpwpTmtMCppyWZpJXuMxKwAFUNe8GfJuBCxC3r4tF8HpfbNUNwPi3AkgAewXggQhbNcgB6K5WFzBeASOZAgJo8ALO69uqMjkAC+hvlidcBmmYBS9he9rFmmMBbFIGm0J4LVe8Io/b9kIeDeGaBHuhrutmY6x72i5VlUxVDAgAA1sOgAP6W9XQTsC7ASgAoqka6ETDdbOpmAAGNrDf/hp60QGgQHlRIQEcw7eqFYjwBP8ksIEEaLqzSXaABzAdYwoXIbXfRIt+PCPArgEozZYFV5vtjOucIbOSKnbzUzKLgQs44LMInjSNjdtXDwRAxwHwcY9/7GiqSkDCUCZ0kr17aavO97MV6LSTuXuBTl/gAg1OcADCnekLhBqrpx2ChUHWC6h98poZw+BX0Pwcq92mOsIGTZxVZxYUHvAe4AyQbq8KaU5ToL0CGC95UXHe9K63qhB/L1wLcIGFTgC9qLD0Yg/NXvwuQNwF+LRmQ/sB70L85FT9wIPh7WrULpfek/nfYRrQNQ5nTD/rKc95RowWOJcTJithxwPoJ9uUgFDhOtXzcacuVwcImeZddmvUqc7/9bh6QN1YJwOe37Twrps9r/FGUWbPzva0ph0Za+eryuU6d7O/fRJjD+Jx6w7WcVeb7Xcfoi6pYDQbIrHsg+W7WVWueKoHng4XzGfc4+rn9FLg0xAPLWcFcOwBy1exC4ZveNHd1/9uWsKmrbkVkrc8O0dlfPiGgGKAQja3hEUIwNnh5OfqZw98egOoV2x3KUCBUBM4xinfuObFLWQJTNnPN6br46fgPs1EBQBOiwBqftnctIQlM9h7izIPv/W9Nly+nw60YiXQ6SRLYO5+Vzn7cZxq5Kc+61mQ/f8CPrHIMMACFiM49MABvIE9uod4dHVtmYZ+UzVjzyZ8C0B8C5AA//CXfJ8lfyhXf/S3V9PnBBPEQdYnDG8hEw9wMe/AHM4RMHmhObunVhzncZ+WAQq1WJvXedulWMWHJxhIfwnwY8wmfapHeCl0cMKATc7hEp6RGhpQezgxfuSnXWeXbG2nVh2oBq8lDi24V/CFClc3hXUVhG/AARtUDlnohWZ4ZGCId2V4hmdYhY2Qd2oidWw4h2iIf3+FgHSYh27IIGuYh4CXhpIAh0rkh4TYV4AYCYJoJlC1iFDlVIz4iDeCVHkmiQ2UiJQoTpdIO5aYidLEiaSziZ6IJaHIOaA4igJRiqbIJanIOKi4iufQiq4ISLGYMLA4i7oCibiYizhii5BQi/+Vw4t0oAG3F3khhImFk28pBoxg8DuEFEmS5BCUlIzK+AXFkRwQYE774k3VBXXE5BBvUUpH1zbTyAU+QQ4WIBOPFAEeE0vdWDgaZkvWlEvjqAVoQRPqQTRFcW/R1IkOYUyogEwG4ITzKAVocY5HYJCg1I7kohP6cUv4NngDOQVoYU57s2EJyY/uSE6nJI4RqSus4YsZBZIs2JEe8pEkWZLGeJJ9UFABJScVwZJw4pIqyQcOxVANtVAPNZN7YFGogFEUwZMC4JM6iQcbBVId5VEcNZR8gFIqZRFMqZR8EFMzZRFSCZV8kFN+gZVWqQc/5RdduZV6QFQ4BZZkWZZm2Yv/upiWfXQKixgHavmWrRAicliIdGmI1jAGxTKXdSlacrmXfmmXfWAkefmXjteXhEmXsyOYbnmYxyWSv8KYhZiYeLmYkDlYjgk5lemHkvmLupKZxWWYXcdsnOUAWxh9WtV4dncKk9mZZ9iDVlWaowlWVud2oFlVE2ByXahVPzhcn+YBM/durtlVnxacwxVYmwkRqWA+8nIzqfV03IiZXwVyXLhXrjmb7+abn7WbWDWb2qmbteloV0ecummaW2VcwWljizdV4pmad4kEgwEbkNSMbiET2PWcRTBQYgdWfBZY4ome69lV3Eme3nkmV7UB7feaHXcB2hYAm/ZnIKdeJZcK/8lXeaowgTCmaFzIY1g2AfBFoQeKZajAYJ4WXwV2YAm2YA02c0ZWh4GpDzJxQTz3and2BCQgAguAAk6ln5hmdQ4wZfg1XvB1J70lXlclnTBmdQ0aaaFFaQJwAdAXACSHpObVWARqVRPoaHgSABcgZA72WYWWY1HGoNQWbT6YfBoYWq65pVWloVk2nGPqX02WfEIGZVJGZVY6XlvWaK3WnshpHrrhP/noaxdZAibwUW7SZfqpCoIWXNFGYzY2YFgGY/NlootVnUKGpmXaXcIVAE8apZcqoFl1mcRSoAd6aH62qX92ZCOHaIpmpYQ2bsGJqae6pj/Wpur5pqfGaSMKav+iRmqm1qCd1oOrFnZ8cA2DgRfoNDhhUZ9kJQQjgCmpsACJo6NWNZsbSlWDpnKzWXckV38BeqYFMH991m3f2nff+XUSp2RqWmBeGmPOBm3SVlUOiGBmGquVCmNqumfexXEcqp6oZ5vqxm5+l2TlpqXo9m3r1mm89W5c1qLuiY7zERmDU1vDBgDQqgoqUDe68I+hwbEa27HCkAobq5dYtZ+CdnXz6nfbqmfweqSfCq6aWmj91aMn22yE9Z1QipuJlqALyqAU96AXp1l3El71Wqb194JBBmj7paAx2HEH+nIoN3f0GgAtx6km134y166FppoPS28E0Emq1Zyg9KwVOq3/0bmjVwdxQApXK3tVp+eyPGi0m2dgD+pds7lpm9pVoroGJOuZg2WtDVusqzkEhGqoOeq3HIiziDtYX6e1W8unI1kENXqjh7u4QFilljuFxxm5R4CfeJm5l7shfQu6jLW570SZpLtWe5ssZoeaZ+W6ocm1ZMiabQiqhGW7Ayq6rTu6oWqmf2eGpjsQqKtV/2mcuLudL7uBZ7W6acC7Wui8WcV40Fu6ssu50Fm7qlta3YlcmCtYFFpfmIdfmocKNghf84WhOrhfTRpgppdejVm9p0u7VDVfumqpPcqwVLUBH0C/AtBpV8pbzmZlIRpgi8WkSAa0fXVoL5YADepn/CVo///Vo02at3uqu1PXe78XfAUwfMVHgUi2q45Gg8zHoM+3vaFbrG0pv96WYNXJqB/gWw5gbkH7bSTXrVh1ZcLnpCcLbTyWX9iavAdst5IaWlfKoknCWOfXr9eKY+LKwBUovdaWgfZKvb04CFJ3m+ZlqVTlmx9XAb6Zs+bFW8C1oLnav0zcflbXra06WuVKrkKmrbkJmEeMWAqYbb+3bBscgQrmwV8KXxcIV/OHqfbHl1WsInAaAF93XnBLVed2Xr2FZeOVyElWAQa2wuCGchw8gS27gdwZwG78d4BbwXOceB13J0osgwtFg+R7eTdYADm4ADsoyMr7mYUcCFIHcneiyP81m78wlm1JFqKpCmVxDLU4loN4ImQIzMbNR3GfDMeBWyHTK1hS6JnrxEPRjFYc57hepWA9S8UWfHZb+MHUjIhWzFgVIHF9R77s+c2pG7u1DCPtrLqKG8+E7CLlTM9f2L347M0Gcs/7bK76/M+0bM+GLNBUys4GbZzkXNAJzb0I3dB6Vc3+DNGhKpdwedGvstC2jNEXfZbx69F7ApMHBdJqUpPSStJqApRCidJiUpQCEFIsnSZPGdNpUpU0nSZaedNl8pU6XSZi2dNAHdRCHSQcXdSxMNQo6QvMu4qiutSp2NRIXQhQHdVWDCFUXdWGcIXCe9W2nARi2BhoAVlTINb/j7NC0DUPMyPW2aMEnsvV+6QPBlB7Yf1cY03XDgGRvYbWQ0SjNoqjbm1PSPAOEQB+rMAA2GgbHwETzPESi1F4qmFnKXEx1CM1jB0T1BQThdcSxWEeOlHZhhcaRVC4qHCof/3WYhEWmt0LcGOQ6bhmf5M6zIVvEUDWrucSFURDn2EAuJRvGgQBcNMSpHQdZMMxN0crZButpQ3YR2CPlqHaM8PctDQz8NBa/BDd2sJrwUYOuA0a1T0/R/PbG3Fze+M1d3SxRn3e6K0jYqRcVeMxCGd7YMMS0p0+oCGGv3R7j30ZHRQanZ3b4WDf1WffVMEewf0WEKA3qwV1xx2ivXI5/9DwfxJENk4HNZgNEwYBN9PtG6kQDhSeMgE3GofxSx+R2xvOYQWhAB2u2f0yHwi+j6ItAKQNJE79RGag1ZA7BJPr18Li4DW+jTd+n0cy48Uw1Vci5FZNRVti5Ei+5EXO40xuJUqu1Efe5Ov95FMS5bmQ3lrusVAuiVhO40j15UPu5fcj5jNi5lb+VmVO5tuD5i3i5lnO5sED50Wy5mFu50dF57eg53KJ50bF56YA6A8i0jLp5EBl0ppoVCqd6EXl0jBNikc10594VDY96UeV05B+VDyd6Zfu58m9JIL+6YlzRluu3pAS6sxARKgOv1Ok6pay6mCO1adO6lL96rROIv+2Tka+ogCVdd2YVSmwPuYWBBMSGwYaYNeaMWvjF+yCq+tGIJ+lIQYAWDih8xa5NevOXgQxOgTbfWInJhLftJwWcOCoYBxCMTgVJD/Oyex7wO5SbkGHATTbLWcuozoSsxX4/d69lmJ1hn0MoDzXXka3jgRysd0GaICKgdmQwUl+Chr8ftvFbZ+C4u5xru2ScRN08z36Vu+TkS27MQQY4z3hUHBMh9cS70ADPwRgixReYS+f4e1IB+7hAWKwJhP7oHQlDxsR36zYHkauDuwp39VAn+2yLvBEryK57vO1PvRKj+tMv0U/3/NQv/RSf0WlTgtJ/+eeruZtLueMnudbH3X/Ya9dY79SFK91s3L1ag9GP3L2hxDsbn9IaiKMQkCMbqSQ2oKMcQ/aasKMyapFz1g40bj3ZKcm1WgXh802bXGRtZNI32hiqBQldVKOHQGx6vj3+9j4xVRL1YRLD2Dyolgn9Vhi+Ag0FYv3SuGPu4A9AYk5e1KQn42QLRb4C0lNDslvtG8mE2nh3mORs4/6qiEZBbGR5yT5twL3Mh4syN/2yp+SzCIrhN7W6BD9Zz4riF4R1//8srLoFfUnQTIrjn6UAhH+3z8rkl4R5//mt1LpFcH+6n8rmF4R8c8ihC8Im14R90//wfLT8g8EAOGQWDQekUnlktl0PqHRpEBatV6x/1ntltv1fsFh8ZhcLlPNafWa3Xa/4XH5vImm3/FWwZ7f9/8BAwUHCQsF2wwTFRcZGw3zII3sIikriSYttzDNNjMRPfM6QUffREmhTMVST1VZ5VZdY79gZY9ovW5rs3J1uXh7gZ1+dYd3g8eKj6WSlZuFmF2hq6SdJauRr7OF8QQIsNmKCahBx7WLys1ZMQ34BpgM3IsGDI7Ep7yT4J/xn9C3icTxoXeOgD0r87oYLKJwISx/6R6mI1fEAAMA4iIs0eeEIUElG6d9AihAwZKOUBCWOYlKYpeILS2tswjgAYIBexpEgMBOQE0+CIggNNBgj8UDew4wGHgAqACiAoAy+P+J4Gc3ADwNQADgdA/QSyKHiCsp5KiAAxm72VNKFoE4cTaRZhSigA8DBU81nCsr1SkAujgh2Btw4GgDCGUP/HUamMrgwlq/wtTyUnIkmQCoRhCQUak4yFfdKVYglJ5Yg2sBMN3qbsADIgwagN43GAKEBu4EsD5wDqyQgHv4HciblgpqpuLcRXiQUYOFoAMtOFfObzUABonp8qPLQXBiCDU7bu+u4LvXIZSvoa/MjeLU3Rd3a+jpDuQQoaFJnl7a1JvY1khl24oABmYawCKrEHjvvN4uIkkICPgS4MCCitvPIKr4UBCAlFS7yjwBNxyomwh4gkowC9Eg8acT2eJtvSv/1HtxjsuE0CwjCwYCQDMFDMhLHnr0oUsBzzbcjYCaQNQgMQE4AEDJq3zshrbDcPMmQRfXwEQsIajSqoEJu7sIvBSXO2KA2ACITkerzvMmpW5gAwACExtDUas452yrzhYjk3EZP7WhUYibnIrgN4sw/PA+v0iyzSwFCkMyQ294IgyzrqzCSisENdyKwS39eiopAe2B1Kkx7auLCOUkvGsPH9sMcZ8jzaJT1tQQcPQAWo/S89YOFwQ0ihiFdYPYO47ts1gkkg2m2WU5kexZT6Fltto6rj1mWjim3fYUb2UBN1uXpGVwXHGjGRcYdLM0N1t2v1W3F3i1SGkKdylJyV4l/zCEKiR5bQG4Fnqz2DdgcEgx+InW/hVYWYdJScWAsibuSQHFDNvqqah+go+PUIsqEqenmiSgrKY2Vmymg9uVgtaaIM1Lg5ys8oxQAUo7+aqnEK1LZYReBsqxxYa48k+Ig0U64o/oocqbA+JhtMncinwttgfysscCixRYbrCLqV4LSQ5co3qwW+9FWIoH3EHgAQi6tiAx6ywiULMmERrbNQNKc5BLASDQlx62MXv76/LkvE6uYZV+pvGl83HHIHhU7ArEK/971EF7yurqTTcNUGyP7DDbTWEs1RhGyGdKoqpJMYU0eh7RSQqSJASeIknw1bcabT9GxzpaaYIfV0Jiyf/RgAdPfzndzsndCL8pzZVvtSrvDzndEM20W44i+rfjnntn6TZLc/APbY8ZAA50RzNv1gz/3ZjGiS/e2sgbFAIeXpm3crdKd4Oho4BsdJ+TlckAlD1WUQ91aQjHA3qCAEi5wwIZYx8++HKAnAEofYQ6igIWCDQIIolDQOGd8JBWP/tZgw1nw9c3wKCwrcWLfivMRLII9QDqpO6FWOja666Ck+BNpIY2rIQKW6E2gCHxiEZsIky65TAmUmKKNqwiLnq4rCuGwolULJcS5bVF9nQREmLURBaLZUY6qHF4X+xeGB/HxhQ6go51tGMfEHFHPe6Rj4CIIxkBaUQ5viuQhSz/3iCvhUhDLhKMjDyDIyGpLkVCa5KRtCQWLwnDTG5yPZVMIydBWRlPCmuUoTTlEkrpp1SekpUNbKUeXhlLbckSC6ukpSlt2clb7jJdvGScL4F5w2D2Y5jFLKMxmZBLZC5SmW5c5jPRaMxmQpOM02yJNakZhz5uk5vd5CMps+lIbAoTUOMMpxNmVqPyNeyUq9hDRqjiDHOekwlUAkADYIVCXKLSUvFsxjzpaRKsHQBuPCvcHqLGsnaisjUDiKerBJDPWAA0oEqQijdm2DUSSfR+rHQnXKSnpukQo6LLMkjnTEQUAyxOofs0Xq7Kgiv9faiXJQWUQWZohJx2dKEvvRQV/0TKpnDZVFgGgWjt4mK8V36ULFSAKEfVQdQuUvSY5ZSqE6nKRate1YpLBSdXGxeCFJzAUydIQQg2GQIUkJUKJ0ABWnUJ1sYtQAB0tSso7VrXusooq3K1ggj8IAJQArYPgn1RX/0qBRKAgA8gIAEoF9vYxx42sUozAR9MYMrL7iGzfK0s0krAhxKYMrR7GK1nPwuxDgigA6xcbWtVmVqIjUAAI2AlbW0bW9k6DLau/epugRtOxAaXuBMt7oy8mVzlHgJGy3Xuc++IyeNyKwDVte51sZtd7W6Xu9317nfBC15oDDda5JoudcObXvWul73tve54LekP8rbTvfW1733ZC//fSMr3vOjF738BHGD9QpK//TVWgBGcYPcOWJz1MMudcoRKAx9YwdjFAF0TsN0EOKC7BRBAhb3LYIgJFVtGEMeoUJPMCSMiuxOowB4WkGHuevi7H+Bwdmm84Q5/uLsCKECCRayE30TYTAM5XRTqU4cdbgiCArDAYfxwsyGSWMUmhgqcSjNCmiZtxQ7ErodlrOMZ87i7G5Cxhm+8XRqDmLtB9ssDGPAZIvxQCYLTQpKTuUP2mbABzslfrC6xZKVamUdJGVzb3tbSLpOBzNXdgARwfAEBXGAC16VrXQPggD04gALWnQAfMMCHClAgxxwuwKUrfWo+YPfSC8hAAHzsYTD/X+C6GRAABSTAhwlM4AKdTkAFsOvmxGmQpjsiQr/sIhCfGbRiODvKA0rCFaj0CwHyeScREBOBCAXPArDSjFYYQmVpS7BmgGNhQ0C4h9D5zW+uXLQqWJ1hD2P6Ahnmdaeru+YELIACFKjAmTMN8FB7oNQBoHQAPEDregdgzdldwAdgXQAwB4ACAsjABBaAgQRs4LoSAPYCKg3yYNdyCTdR0FESemzA2Xl6byZR06wCteowbCNMUoJwQITtqK0u3Ds0m2sIRDdFN6gkUjk0k+XM5XcjA7uP9nTGBYCB6kbdumuWAKQDkACsV9cBGc6ApvcwgVKHug+hlnrDKZ7rPUA6/9Zk/ncFJiABM2dd0pjesAcWkF1hQ4jYRTjMh3DHB98Nail9QIA+Jlclom9kMBL6DIRUReVuD+Hbf96HR0wD7XY/zDcOokuWI8jTpcP7uh4QAMSznveFJ6DXVb916vsd4+t2PQAep7gAxP5hHR/cuqtv9Kc7XQG2S5zMrIf0BS6QgYEH4AN5p8AF/q13khuha3F+TWgINwScs2807kPTTmWT+CT9T6JI+puXDgTEv/HZzz33yJPGJ/r5jZ7p2HUxjOUtad5X19+YBjunZy//9Cr3ss7UWi0APk0AXuy6MODF6mr4Gs7Wfqz5uA7G8o75Wm/kYOQIaCeAysLPUqVWQP8IghhggY6KR5BHf3ADKawEoZosY+ZCVOpmdIKiyZ6s886DBnPQLPDhguRv+uiP9NhsCAGM9qRvA6lI0CDhyKjFF4Kw/ogwCuvL9PBNA2EpCT2Bzn4QCZ8QDBpNCsHwv4QtkAqsC2chDNFQDIFQnLjJDL1wCNHOveJQCsfwhpRQq9wwJuDwC8WL+PKND6OwDrmACafhDrNgJYpAZbYwD5FlD+WQx+YwENfwWwwRCxDxCGxk6BixEQOM7BSQ1D6sAfngx/4PFD3s01StrjzsxZIP1i5N7YANwYTNgwzF5r5EYywHgfwFHiYGaHRm3AjIOSwAMI6KOoKmSCAoY4ZxMeb/4SYwBsrMIohwhjHeYi42T+k2kRsqbOBobANi0cf2rd/+beIibs1kLdPYLsMkIONC7ccEbBJrpEyaY30eAEeeAX5oAijIZmdK4nroceZ2wx4HJWNuQyBJjHDcJnAIikrOxEsGYDCoQzzQYEpuAznsw/zOLRtDAcG+TtdoTOQi7uqqS+saru3+sLpE0scKcOrcEcDcrF+i0TrMDUTEwg9QkPBoh3SuBFgiREI6RKh4R3cGoiJ6kgFSonJsReg2hAEYAlgyUiM5EcBsr+IIcAM4TgLDkQJirCSJr9OsbvhWMuJkER51pEyGgAM0SES84UkwMkD8MVauRCC15zOCijq+/ydw6KFrbAIGb2V59EQrpgRqLvEpoXJGEKwAJI2uCDAD8ooUNw0UrcvH+m8BvlIsxUwl35EL5aEuMOIwDoQFPSYaGW+DojF7IEoYfyICCoPEjvFm/GwZoSIl+CdXiOJ/1I0xsG3LsLEwtQkNbU3q0rC9BPEeLIEQHYg3tTEK500AAC441Ws4maUS48A4yws5DdM5sfM5ybKQ5sumADE7wfMIr5DArHONwvM822w7ybA8rxM93TMy1ROQurOkvvM9sxM6BYk9X8E+7RM/u0o/uQW6BLSbamlADfRAAwFAFXT+FrRBzWE+HXQTITRC83BCKdQMLfRCnzBDNZT+OLRDl//uQ0G0pPBpUAhqPEc0RcvARrSQnVT0RcPgTNREF4HC2tZpEWE0R7PgABJNb7ZC/bhHR4V0CxAiJxvP+oJ0SJX0IAaiLYfASQFArdgKANwKrpb0Sp1ANhHjOwDjCPLqrrA0TMmAsPjAsMT0TL8gsvbAsdC0Tb1gswSgs9x0TrOgtATgtOg0T63gtfS0T6sAt/w0UKGgtwS1UA31UBEVRhF0UesoUZ+pPvkzOEXUUZMzUs9zUinVPC31UjNVmjaVUzt1mCD1U+kwVEU1Ci+MOdFsxyTVVIOJD++vrprzy0aV+dLsugpuzEKsJV3SVYHpC8lRzNSsVueOu4RVuyKRCDH/1VdZ7Lqc7sv0r9Ks6wBL0dNATdQgU8dSMdUu7Qtb7dXabtZq7dbUDvfuLetiET6ZdZe8Vd5gzODsLQMZjseyMvqsywirixt1j8MOLuHgdV636+HKUVUr7uIybuM67uNCTlrVdV1p6QufFQGhDjip7iRrD+u0LgADoCPDbuz8wOwA1rpwjQ8g0O1+Le7mjvXe9e4u8L0c9pa+0PRQb9/+lfWq0MN8jd+0EuBobypxr+D2r2Z/7/WEb2Cty/gMLvmWjwKfz15d9mVlCVYdUPYQc9IYluJeLO+q9V4FUDELLhXzLgEX0LpE8QGNtrokkPkuEOwW4AI/QF4bFmpbqVZJ//W/8PVp5XZu65YIqVC7ljVvoXBv0/BvATcM6FZwFYxwC/cM2SxZ1ctx2UxxF9clHHG9TDJk0VByJ1cTKpe9zPFwx3JzQQl0wcsTR43GylYlS1HWcM/HWm0VJw1cX3EP0rVXRZeTSDe99DUAvJEl6zUByPFyz9EB0rH22BEzbfd2Myl3vYtjf/bDQNLHRDLrJIArPxclwfIyeRW/NFd59QDBfLYqrxIcdXYryaztvJLHUvLHtDd0vTe+DjMxn3djGzPTHpMrJ7MyVbJ9M/N998s3K7Zuu9d/UUEKl3NWN3WACVgYELdVF1icGnhwHxiCIzgMFXiCjaeCLRiDmUmDwS3wgjnYFjy4VEOYDBn1hBehhFV4hVm4hV34hWE4hmV4hmm4hm34hnE4h4spCAAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The crash airway algorithm&copy;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 463px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Difficult Airway Course&reg;: Emergency and Walls RM, Murphy MF. Manual of Emergency Airway Management,&nbsp;4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8611=[""].join("\n");
var outline_f8_26_8611=null;
var title_f8_26_8612="Icosapent ethyl (E-EPA): Drug information";
var content_f8_26_8612=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Icosapent ethyl (E-EPA): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/58/11172?source=see_link\">",
"    see \"Icosapent ethyl (E-EPA): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15162621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vascepa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14717677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, Omega-3 Fatty Acids",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15162678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Hypertriglyceridemia:",
"     </b>",
"     Oral: 2 g twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15162679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15162680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); however, not renally eliminated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15162681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); periodic monitoring of ALT and AST is recommended in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15887579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid gel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vascepa&trade;: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15162622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15162683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food. Swallow whole; do not chew, crush, or divide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14717568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy in the treatment of hypertriglyceridemia (&ge;500 mg/dL)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15162631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Neuromuscular &amp; skeletal: Arthralgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Oropharyngeal pain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15162627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to icosapent ethyl or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15162628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fish allergy: Use with caution in patients with known allergy or sensitivity to fish and/or shellfish.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Prolongation of bleeding time: Prolongation of bleeding time not exceeding normal limits has been observed in some clinical studies of omega-3 fatty acids; clinically significant bleeding episodes did not occur. Use with caution in patients with coagulopathy or in those receiving therapeutic anticoagulation; monitor for changes in INR (with warfarin) or signs/symptoms of bleeding following initiation and dosage changes of icosapent ethyl and in patients receiving concomitant anticoagulant or antiplatelet therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Studies have not been conducted in patients with hepatic impairment; however, ALT/AST levels should be monitored periodically during therapy in hepatically impaired patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Medications known to worsen hypertriglyceridemia (eg, beta-blockers, thiazides, estrogens) should be discontinued or changed prior to initiation of triglyceride-lowering therapy if possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Should be used as an adjunct to diet therapy and exercise and only in those with very high triglyceride levels (&ge;500 mg/dL). Secondary causes of hyperlipidemia should be ruled out prior to therapy. The effect, if any, of icosapent ethyl on the risk of pancreatitis or cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia is not known.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15255923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15255921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Omega-3 Fatty Acids may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15162638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Monitor ethanol use (alcohol use may increase triglycerides).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15162623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15162624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Maternal dietary consumption of omega-3-fatty acids (containing eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) influences fetal concentrations (Coletta, 2010; Miles, 2011). Information specific to the therapeutic use of this product in pregnancy has not been located; however, the use of omega-3-fatty acids to manage elevated triglycerides in pregnancy has been described in case reports (Goldberg, 2012; Papadakis, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15162625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15162626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal dietary consumption of omega-3-fatty acids (containing eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) influences milk concentrations (Coletta, 2010; Miles, 2011). Information specific to the therapeutic use of this product by nursing women has not been located.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15162650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food. Dietary modification is important in the control of severe hypertriglyceridemia. Maintain standard cholesterol-lowering diet during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vascepa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (120): $220.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15162698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Triglycerides and other lipids (LDL-C) should be monitored at baseline and periodically. In patients with hepatic impairment, monitor ALT and AST periodically during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15162641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Icosapent ethyl, the ethyl ester of eicosapentaenoic acid (EPA), is an omega-3 fatty acid which aids in decreasing hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis/secretion and increasing triglyceride clearance from VLDL particles. The mechanism has not been completely defined. Possible mechanisms include inhibition of acyl CoA: 1,2 diacylglycerol acyltransferase, increased hepatic beta-oxidation, a reduction in the hepatic synthesis of triglycerides, or an increase in plasma lipoprotein lipase activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15162643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: De-esterified to active metabolite (EPA) which is absorbed in the small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : EPA: ~88 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Mainly hepatic via beta-oxidation; minor via CYP 450",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life Elimination: EPA: ~89 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: EPA: ~5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Not renally excreted",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bays HE, Ballantyne CM, Kastelein JJ, et al, &ldquo;Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week study With an Open-label Extension [Marine] Trial,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2011, 108(5):682-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8612/abstract-text/21683321/pubmed\" id=\"21683321\" target=\"_blank\">",
"        21683321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8612/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coletta JM, Bell SJ, and Roman AS, \"Omega-3 Fatty Acids and Pregnancy,\"",
"      <i>",
"       Rev Obstet Gynecol",
"      </i>",
"      , 2010, 3(4):163-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8612/abstract-text/21364848/pubmed\" id=\"21364848\" target=\"_blank\">",
"        21364848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldberg AS and Hegele RA, \"Severe Hypertriglyceridemia in Pregnancy,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(8):2589-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8612/abstract-text/22639290/pubmed\" id=\"22639290\" target=\"_blank\">",
"        22639290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miles EA, Noakes PS, Kremmyda LS, et al, \"The Salmon in Pregnancy Study: Study Design, Subject Characteristics, Maternal Fish and Marine N-3 Fatty Acid Intake, and Marine N-3 Fatty Acid Status in Maternal and Umbilical Cord Blood,\"",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 2011, 94(6 Suppl):1986-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8612/abstract-text/21849598/pubmed\" id=\"21849598\" target=\"_blank\">",
"        21849598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller M, Stone NJ, Ballantyne C, et al, &ldquo;Triglycerides and Cardiovascular Disease: A Scientific Statement from the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(20):2292-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8612/abstract-text/21502576/pubmed\" id=\"21502576\" target=\"_blank\">",
"        21502576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Papadakis EP, Sarigianni M, and Mikhailidis DP, \"Acute Pancreatitis in Pregnancy: An Overview,\"",
"      <i>",
"       Eur J Obstet Gynecol Reprod Biol",
"      </i>",
"      , 2011, 159(2):261-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8612/abstract-text/21840110/pubmed\" id=\"21840110\" target=\"_blank\">",
"        21840110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86044 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8612=[""].join("\n");
var outline_f8_26_8612=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162621\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14717677\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162678\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162679\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162680\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162681\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15887579\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162622\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162683\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14717568\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162631\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162627\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162628\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255923\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255921\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162638\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162623\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162624\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162625\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162626\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162650\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570447\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162698\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162641\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162643\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86044\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86044|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/58/11172?source=related_link\">",
"      Icosapent ethyl (E-EPA): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_26_8613="Ergotamine and caffeine: Pediatric drug information";
var content_f8_26_8613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ergotamine and caffeine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42885?source=see_link\">",
"    see \"Ergotamine and caffeine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/9/35988?source=see_link\">",
"    see \"Ergotamine and caffeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cafergot&reg;;",
"     </li>",
"     <li>",
"      Migergot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cafergor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ergot Alkaloid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42885?source=see_link\">",
"      see \"Ergotamine and caffeine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Not for chronic daily administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 2 mg at onset of attack; then 1-2 mg every 30 minutes as needed; maximum dose: 6 mg per attack; do not exceed 10 mg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal, suppositories: 1 suppository at first sign of an attack; follow with second dose after 1 hour, if needed; maximum dose: 2 per attack; do not exceed 5/week",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Migergot&reg;: Ergotamine tartrate 2 mg and caffeine 100 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Ergotamine tartrate 1 mg and caffeine 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cafergot&reg;: Ergotamine tartrate 1 mg and caffeine 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Tablets may be taken without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevent or abort vascular headaches, such as migraine and migraine variants also known as &ldquo;histaminic cephalalgia&rdquo;",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F166427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cafergot&reg; may be confused with Carafate&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F166425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Absence of pulse, bradycardia, cardiac valvular fibrosis, cyanosis, ECG changes, edema, gangrene, hypertension, ischemia, precordial distress and pain, tachycardia, vasospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anal or rectal ulcer (with overuse of suppository), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Retroperitoneal fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle pain, numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pleuropulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ergotamine, caffeine, or any component; pregnancy; peripheral vascular disease, hepatic or renal disease, hypertension, peptic ulcer disease, sepsis, coronary heart disease; concurrent therapy with potent CYP3A4 inhibitors (eg, protease inhibitors and macrolide antibiotics)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term use is associated with fibrotic changes to heart, pulmonary valves, and rare cases of retroperitoneal fibrosis; chronic usage may also be harmful due to a reduction in cerebral blood flow, ECG changes, and hypertension; sustained vasoconstriction may precipitate angina or MI, aggravate intermittent claudication, or lead to ischemic colitis. Concomitant use with potent inhibitors of CYP3A4 (including protease inhibitors and macrolide antibiotics) has been associated with acute ergot toxicity characterized by serious and/or life-threatening cerebral and peripheral ischemia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; some cases have resulted in amputation; less potent CYP3A4 inhibitors (eg, metronidazole, fluoxetine, nefazodone, zileuton, and azole antifungals) may carry the same risk. Patients who take ergotamine for extended periods of time may become dependent on it and discontinuation may result in withdrawal symptoms (eg, rebound headache). Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Ergotamine. Management: Avoid ergotamine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid tea, cola, and coffee (caffeine may increase GI absorption of ergotamine). Avoid grapefruit juice; may cause increased blood levels of ergotamine, leading to increased toxicity",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause prolonged constriction of the uterine vessels and/or increased myometrial tone leading to reduced placental blood flow. This has contributed to fetal growth retardation in animals.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha-adrenergic receptors depending upon their site; is a highly active uterine stimulant; it causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers; caffeine is also a vasoconstrictor which was added to potentially enhance ergotamine's effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: Erratic; absorption is enhanced by caffeine coadministration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Poor overall (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 0.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In bile as metabolites (90%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/9/35988?source=see_link\">",
"      see \"Ergotamine and caffeine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Any symptoms such as nausea, vomiting, numbness or tingling, and chest, muscle, or abdominal pain should be reported to the physician at the first sign of an attack; do",
"     <b>",
"      not",
"     </b>",
"     exceed recommended dosage; not for chronic daily use; avoid coffee, tea, cola, and grapefruit juice; may cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12850 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8613=[""].join("\n");
var outline_f8_26_8613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708747\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166389\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058465\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058460\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166367\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166354\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058469\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058468\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166427\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166425\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058472\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058458\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166416\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166362\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058473\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166364\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166375\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058457\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058471\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058464\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12850|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42885?source=related_link\">",
"      Ergotamine and caffeine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/9/35988?source=related_link\">",
"      Ergotamine and caffeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_26_8614="Psyllium: Drug information";
var content_f8_26_8614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Psyllium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/23/21876?source=see_link\">",
"    see \"Psyllium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/34/1573?source=see_link\">",
"    see \"Psyllium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bulk-K [OTC];",
"     </li>",
"     <li>",
"      Fiberall&reg; [OTC];",
"     </li>",
"     <li>",
"      Fibro-Lax [OTC];",
"     </li>",
"     <li>",
"      Fibro-XL [OTC];",
"     </li>",
"     <li>",
"      Hydrocil&reg; Instant [OTC];",
"     </li>",
"     <li>",
"      Konsyl-D&trade; [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Easy Mix&trade; [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Orange [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Original [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; Plus Calcium [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; Smooth Texture [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; [OTC];",
"     </li>",
"     <li>",
"      Natural Fiber Therapy Smooth Texture [OTC];",
"     </li>",
"     <li>",
"      Natural Fiber Therapy [OTC];",
"     </li>",
"     <li>",
"      Reguloid [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metamucil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiarrheal;",
"     </li>",
"     <li>",
"      Fiber Supplement;",
"     </li>",
"     <li>",
"      Laxative, Bulk-Producing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General dosing guidelines; consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake for total fiber:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     The definition of &ldquo;fiber&rdquo; varies; however, the soluble fiber in psyllium is only one type of fiber which makes up the daily recommended intake of total fiber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults 19-50 years: Males: 38 g/day; Females: 25 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults &ge;51 years: Males: 30 g/day; Females: 21 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnancy: 28 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactation: 29 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Oral: Psyllium: 2.5-30 g per day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Reduce risk of CHD:",
"     </b>",
"     Oral: Soluble fiber &ge;7 g (psyllium seed husk &ge;10.2 g) per day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/34/1573?source=see_link\">",
"      see \"Psyllium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     General dosing guidelines; consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake for total fiber:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     The definition of &ldquo;fiber&rdquo; varies; however, the soluble fiber in psyllium is only one type of fiber which makes up the daily recommended intake of total fiber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-3 years: 19 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-8 years: 25 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 9-13 years: Males: 31 g/day; Females: 26 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 14-18 years: Males: 38 g/day; Females: 26 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years: Psyllium: 1.25-15 g per day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Reduce risk of CHD:",
"     </b>",
"     Oral: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fibro-XL: 0.675 g [sugar free; provides dietary fiber 3.8 g and soluble fiber 3 g per 7 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg;: 0.52 g [sugar free; contains calcium 8 mg/capsule, potassium &lt;11 mg/capsule, sodium 1 mg/capsule; provides dietary fiber 3 g and soluble fiber 2 g per 5 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;: 0.52 g [contains potassium 5 mg/capsule; provides dietary fiber 3 g and soluble fiber 2.1 g per 6 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Plus Calcium: 0.52 g [contains calcium 60 mg/capsule, potassium 6 mg/capsule; provides dietary fiber 3 g and soluble fiber 2.1 g per 5 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid: 0.52 g [provides dietary fiber 3 g and soluble fiber 2 g per 6 capsules]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:  (454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bulk-K:  (392 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fiberall&reg;:  (454 g) [sugar free; contains phenylalanine; orange flavor; psyllium is in combination with other fiber sources;  also contains vitamins and minerals]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fibro-Lax:  (140 g, 392 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocil&reg; Instant:  (300 g) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocil&reg; Instant: 3.5 g/packet (30s, 500s) [sugar free; provides dietary fiber 3 g and soluble fiber 2.4 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl-D&trade;:  (325 g, 397 g, 500 g) [contains calcium, dextrose, potassium, sodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl-D&trade;: 3.4 g/packet (100s, 500s) [contains calcium 6 mg/packet, dextrose 3.1 g/packet, potassium 31 mg/packet, sodium 3 mg/packet; provides dietary fiber 3 g and soluble fiber 2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Easy Mix&trade;:  (250 g) [sugar free; contains calcium, potassium, sodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Easy Mix&trade;: 6 g/packet (500s) [sugar free; contains calcium 10 mg/packet, potassium 55 mg/packet, sodium 5 mg/packet; provides dietary fiber 5 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Orange:  (538 g) [contains calcium, potassium, sodium, sucrose; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Orange: 3.4 g/packet (30s) [contains calcium 6 mg/packet, potassium 31 mg/packet, sodium 3 mg/packet, sucrose 8 g/packet; orange flavor; provides dietary fiber 3 g and soluble fiber 2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Orange:  (425 g) [sugar free; contains calcium, phenylalanine, potassium, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Original:  (300 g, 450 g) [sugar free; contains calcium, potassium, sodium]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Konsyl&reg; Original: 6 g/packet (30s, 100s, 500s) [sugar free; contains calcium 10 mg/packet, potassium 55 mg/packet, sodium 5 mg/packet; provides dietary fiber 5 g and soluble fiber 3 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;:  (390 g, 570 g, 870 g) [contains potassium, sodium; unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;:  (570 g, 870 g, 1254 g) [contains potassium, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (609 g, 912 g, 1368 g) [contains potassium, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture: 3.4 g/packet (30s) [contains potassium 30 mg/packet, sodium 5 mg/packet; orange flavor; provides dietary fiber 3 g and soluble fiber ~2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (283 g, 425 g, 660 g) [sugar free; contains phenylalanine, potassium, sodium; berry burst flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (173 g, 300 g, 450 g, 660 g, 1020 g) [sugar free; contains phenylalanine, potassium, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (288 g, 432 g, 684 g) [sugar free; contains phenylalanine, potassium, sodium; pink lemonade flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture:  (300 g, 450 g, 690 g) [sugar free; contains potassium, sodium; unflavored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture: 3.4 g/packet (30s) [sugar free; contains phenylalanine 16 mg/packet, potassium 30 mg/packet, sodium 5 mg/packet; berry burst flavor; provides dietary fiber 3 g and soluble fiber ~2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg; Smooth Texture: 3.4 g/packet (30s) [sugar free; contains phenylalanine 25 mg/packet, potassium 30 mg/packet, sodium 5 mg/packet; orange flavor; provides dietary fiber 3 g and soluble fiber ~2 g per packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natural Fiber Therapy:  (390 g, 539 g) [natural flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natural Fiber Therapy:  (390 g, 539 g) [contains sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Natural Fiber Therapy Smooth Texture:  (300 g) [sugar free; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid:  (369 g, 540 g) [contains sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid:  (369 g, 540 g) [contains sodium; regular flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid:  (284 g, 426 g) [sugar free; contains phenylalanine, sodium; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reguloid:  (284 g, 426 g) [sugar free; contains phenylalanine, sodium; regular flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wafer, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;: 3.4 g/2 wafers (24s) [contains potassium 60 mg/2 wafers, sodium 20 mg/2 wafers, soya lecithin; apple flavor; provides dietary fiber 6 g and soluble fiber 3 g per 2 wafers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metamucil&reg;: 3.4 g/2 wafers (24s) [contains potassium 60 mg/2 wafers, sodium 20 mg/2 wafers, soya lecithin; cinnamon-spice flavor; provides dietary fiber 6 g and soluble fiber 3 g per 2 wafers]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes wafers",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F215635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation of psyllium dust may cause sensitivity to psyllium (eg, runny nose, watery eyes, wheezing). Drink at least 8 ounces of liquid with each dose. Powder must be mixed in a glass of water or juice. Capsules should be swallowed one at a time. When more than one dose is required, they should be divided throughout the day. Separate dose by at least 2 hours from other drug therapies.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     OTC labeling: Dietary fiber supplement; treatment of occasional constipation; reduce risk of coronary heart disease (CHD)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5539745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diarrhea, chronic constipation, irritable bowel syndrome, inflammatory bowel disease, colon cancer, or diabetes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fiberall&reg; may be confused with Feverall&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, constipation, diarrhea, esophageal or bowel obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis upon inhalation in susceptible individuals, rhinoconjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to psyllium or any component of the formulation; fecal impaction; GI obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary heart disease (CHD): To reduce the risk of CHD, the soluble fiber from psyllium should be used in conjunction with a diet low in saturated fat and cholesterol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with esophageal strictures, ulcers, stenosis, or intestinal adhesions or difficulty swallowing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may have insufficient fluid intake which may predispose them to fecal impaction and bowel obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium: Some products may contain calcium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium: Some products may contain potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium: Some products may contain sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Soy lecithin: Some products may contain soy lecithin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Products must be taken with at least 8 ounces of fluid in order to prevent choking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), do not use in the presence of abdominal pain, nausea, or vomiting. Notify healthcare provider in case of sudden changes of bowel habits which last &gt;2 weeks or in case of rectal bleeding. Not for self-treatment of constipation lasting &gt;1 week.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14191258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Psyllium is not absorbed systemically. When administered with adequate fluids, use is considered safe for the treatment of occasional constipation during pregnancy (Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F215639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Products should be taken with at least 8 ounces of fluids. Some products may contain phenylalanine, potassium, sodium, as well as additional ingredients. Check individual product information for caloric and nutritional value.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     When used to reduce the risk of CHD, the amount of",
"     <b>",
"      soluble fiber",
"     </b>",
"     from psyllium should be &ge;7 g/day and it should be used in conjunction with a diet low in saturated fat and cholesterol.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Konsyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     520 mg (100): $6.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Metamucil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.52 g (160): $14.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Hydrocil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     95% (30): $13.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Konsyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     28.3% (30): $8.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100% (30): $10.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Konsyl-D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     52.3% (100): $18.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Metamucil MultiHealth Fiber Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     58.12% (30): $9.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Metamucil Smooth Texture Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     28% (30): $9.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Hydrocil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     95% (300 g): $13.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Konsyl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     28.3% (538 g): $9.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30.9% (397 g): $4.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60.3% (450 g): $9.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     71.67% (300 g): $10.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100% (300 g): $12.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Konsyl-D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     52.3% (397 g): $4.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Metamucil MultiHealth Fiber Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     58.6% (425 g): $11.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     63% (660 g): $15.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Metamucil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30.9% (822 g): $11.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     48.57% (822 g): $15.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Metamucil Smooth Texture Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     28.3% (861 g): $11.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     58.6% (425 g): $11.53",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Colofiber (BE);",
"     </li>",
"     <li>",
"      Euromucil (PE);",
"     </li>",
"     <li>",
"      Fiberad (PK);",
"     </li>",
"     <li>",
"      Fibermate (PH);",
"     </li>",
"     <li>",
"      Fibral (CO);",
"     </li>",
"     <li>",
"      Fibrocol (PK);",
"     </li>",
"     <li>",
"      Fibrolax (IT);",
"     </li>",
"     <li>",
"      Fybogel (GB, IE, MY, NZ, SG, TH);",
"     </li>",
"     <li>",
"      Konsyl (IL, TW);",
"     </li>",
"     <li>",
"      Laxamucil (FI);",
"     </li>",
"     <li>",
"      Lunelax (SE);",
"     </li>",
"     <li>",
"      Metamucil (AR, CN, HK, NL, NZ, TH);",
"     </li>",
"     <li>",
"      Mucofalk (ID, MY, PH, SG);",
"     </li>",
"     <li>",
"      Mucofalk Orange (BG, EE);",
"     </li>",
"     <li>",
"      Mulax (ID);",
"     </li>",
"     <li>",
"      Pal Mucil Polvo Vegetal Fino (PY);",
"     </li>",
"     <li>",
"      Plenum (UY);",
"     </li>",
"     <li>",
"      Regulan (GB, IE);",
"     </li>",
"     <li>",
"      Transilane (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Psyllium is a soluble fiber. It absorbs water in the intestine to form a viscous liquid which promotes peristalsis and reduces transit time.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Relief of constipation: 12-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: None; small amounts of grain extracts present in the preparation have been reportedly absorbed following colonic hydrolysis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)",
"      </i>",
"      , Washington, DC: The National Academies Press, 2005.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James SL, Muir JG, Curtis SL, et al, &ldquo;Dietary Fibre: A Roughage Guide,&rdquo;",
"      <i>",
"       Intern Med J",
"      </i>",
"      , 2003, 33(7):291-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8614/abstract-text/12823674/pubmed\" id=\"12823674\" target=\"_blank\">",
"        12823674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh B, &ldquo;Psyllium as Therapeutic and Drug Delivery Agent,&rdquo;",
"      <i>",
"       Int J Pharm",
"      </i>",
"      , 2007, 334(1-2):1-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8614/abstract-text/17329047/pubmed\" id=\"17329047\" target=\"_blank\">",
"        17329047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wald A, \"Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy,\"",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2003, 32(1):309-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8614/abstract-text/12635420/pubmed\" id=\"12635420\" target=\"_blank\">",
"        12635420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9834 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.102.30.19-5FA4BE6EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8614=[""].join("\n");
var outline_f8_26_8614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215645\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215646\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215660\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215648\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215656\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215649\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215631\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215618\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215635\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215634\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539745\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215667\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215658\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215638\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215622\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299962\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215627\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14191258\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215639\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323759\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390211\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215621\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215637\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9834|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/23/21876?source=related_link\">",
"      Psyllium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/34/1573?source=related_link\">",
"      Psyllium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_26_8615="Crohns granuloma Light";
var content_f8_26_8615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Granulomatous inflammation in a biopsy from a patient with Crohn disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Glickman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8615=[""].join("\n");
var outline_f8_26_8615=null;
var title_f8_26_8616="Acquired torticollis in children";
var content_f8_26_8616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired torticollis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/26/8616/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8616/contributors\">",
"     Charles G Macias, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8616/contributors\">",
"     Vanthaya Gan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/26/8616/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8616/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8616/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8616/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8616/contributors\">",
"     Glenn C Isaacson, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/26/8616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8616/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/26/8616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torticollis is the term for the clinical finding of a twisted or rotated neck. In Latin, the word \"torus\" means \"twisted\" and \"collum\" means \"neck\". Torticollis, also called wryneck, is a common complaint in children and may be congenital or acquired. Facial asymmetry is often present in children who have congenital torticollis, but rarely in those with acquired torticollis, and is sometimes used to distinguish the two types [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/1\">",
"     1",
"    </a>",
"    ]. Congenital torticollis is more common than acquired torticollis.",
"   </p>",
"   <p>",
"    The causes, presentation, and evaluation of acquired torticollis will be reviewed below. Congenital muscular torticollis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43798?source=see_link\">",
"     \"Congenital muscular torticollis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury or inflammation from a variety of conditions can cause spasm of cervical muscles or irritation of cervical nerves, resulting in torticollis. Underlying conditions range in severity from benign (eg, pharyngitis) to potentially life-threatening (eg, retropharyngeal abscess, vertebral subluxation, spinal epidural hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/2\">",
"     2",
"    </a>",
"    ]) (",
"    <a class=\"graphic graphic_table graphicRef76604 \" href=\"UTD.htm?18/19/18749\">",
"     table 1",
"    </a>",
"    ). The most common causes include minor trauma, upper respiratory tract infection, cervical lymphadenitis, myositis, retropharyngeal abscess, and superior oblique palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. Less common causes include benign paroxysmal torticollis, dystonic reaction, and Sandifer syndrome. Several of these causes are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Atlantoaxial rotary subluxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atlantoaxial subluxation, a rotational displacement of C1 on C2, is another important cause of acquired torticollis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/8\">",
"     8",
"    </a>",
"    ]. Atlantoaxial subluxation is thought to be caused by retropharyngeal edema that leads to laxity of the ligaments and capsular structures at the atlantoaxial level and permits rotary deformity. Children between 6 and 12 years of age are affected most frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/3\">",
"     3",
"    </a>",
"    ]. Atlantoaxial subluxation may occur after minor trauma, pharyngeal surgery, an inflammatory process of the neck (causing spasm of the SCM), or upper respiratory tract infection. Nontraumatic atlantoaxial subluxation is sometimes called Grisel syndrome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59495 \" href=\"UTD.htm?3/5/3153\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most children present with pain and decreased range of motion following minor trauma or infection of the head and neck. In contrast to congenital muscular torticollis, the head tilts away from the affected SCM muscle so that the SCM muscle on the \"chin\" side is tight and tender [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. Children with atlantoaxial rotary subluxation also may have tenderness of the spinous process of the axis, displacement of the spine of the axis to the same side as the torticollis, reduction in the size of the nasopharynx, and a change in nasal resonance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, because a portion of the second cervical nerve (which innervates the occipital dermatome) runs in the capsule of the atlantoaxial joint, they may complain of unilateral occipital pain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of atlantoaxial subluxation includes fractures, tumors, and osteomyelitis of the upper cervical spine, and tumors of the posterior fossa or spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervical spine immobilization and cervical radiographs are warranted, particularly when there is a clear traumatic mechanism of injury. In addition, cervical spine radiographs should be obtained in patients who have conditions that are associated with atlantoaxial instability (eg, Down syndrome, Morquio syndrome, Larsen syndrome, Marfan syndrome, and cervical spine arthritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Torticollis or neck pain in patients with these conditions, particularly when associated with neurologic symptoms (eg, gait abnormalities, clumsiness, change in bowel or bladder habits, hyperreflexia) may indicate spinal cord injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/14,15,21\">",
"     14,15,21",
"    </a>",
"    ]. The cervical spine should be immobilized before imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic evaluation demonstrates asymmetry of the odontoid in relation to the atlas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/8\">",
"     8",
"    </a>",
"    ]. Open-mouth views of the odontoid demonstrate the best view, but may be difficult to obtain because the limited range of motion prevents proper positioning [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/12\">",
"     12",
"    </a>",
"    ]. Dynamic CT, with the head turned (actively, never passively) as far as possible to the right and to the left, may be necessary to verify the subluxation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for atlantoaxial subluxation depends upon the severity and duration of the abnormality. For acute (less than one week in duration) and minor cases, soft cervical collar, rest, and analgesics may be adequate. For severe cases, cervical traction followed by immobilization and surgical intervention may be indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Orthopedic consultation should be obtained when the pain is severe. Neurosurgical consultation should be obtained when there is evidence of neurologic deficit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Retropharyngeal abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various respiratory and soft tissue infections of the neck may cause acquired torticollis in children (",
"    <a class=\"graphic graphic_table graphicRef76604 \" href=\"UTD.htm?18/19/18749\">",
"     table 1",
"    </a>",
"    ). Among these, retropharyngeal abscess is potentially life-threatening (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51505 \" href=\"UTD.htm?11/46/12015\">",
"     image 2",
"    </a>",
"    ). Retropharyngeal abscess occurs most commonly in children between the ages of two and four years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/28\">",
"     28",
"    </a>",
"    ]. Unwillingness to move the neck because of discomfort is a prominent presenting feature. Additional signs and symptoms of retropharyngeal abscess include fever, irritability, dysphagia, drooling, odynophagia, and respiratory distress (stridor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tachypnea). Retropharyngeal abscess is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ocular torticollis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have disorders of ocular motility or alignment (strabismus) may tilt their heads to avoid diplopia. These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/12999?source=see_link\">",
"     \"Fourth cranial nerve (trochlear nerve) palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation and management of strabismus in children\", section on 'Strabismus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43046?source=see_link&amp;anchor=H3#H3\">",
"     \"Sixth cranial nerve (abducens nerve) palsy in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Spasmus nutans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spasmus nutans includes a triad of acquired nystagmus, head nodding, and torticollis. The presence of all three features is not necessary for diagnosis; head nodding and nystagmus are most common, with head turn in only 30 percent. The age at onset is usually 6 to 12 months, but can be up to several years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/29\">",
"     29",
"    </a>",
"    ]. This disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1034?source=see_link&amp;anchor=H9#H9\">",
"     \"Pendular nystagmus\", section on 'Spasmus nutans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Benign paroxysmal torticollis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign paroxysmal torticollis is a self-limited condition characterized by recurrent episodes of head tilt often accompanied by vomiting, pallor, irritability, ataxia, or drowsiness that usually presents in the first few months of life. The periodic episodes of torticollis can randomly alternate from side to side. The individual attacks typically last for hours, but occasionally last for days. The episodes occur less frequently as the child gets older and disappear in most cases by five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of benign paroxysmal torticollis has not been determined. It is considered to be a \"migraine equivalent\" disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/32\">",
"     32",
"    </a>",
"    ]. Some patients go on to develop migraine headaches or benign paroxysmal vertigo of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/33\">",
"     33",
"    </a>",
"    ]. Electromyographics studies in one infant demonstrated continuous electrical discharges over the sternocleidomastoid muscle during the episodes, indicating that the torticollis was a dynamic phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benign paroxysmal torticollis is occasionally confused with congenital muscular torticollis. However, in contrast to congenital muscular torticollis, the torticollis is usually accompanied by vomiting, pallor, irritability, ataxia, or drowsiness. The associated findings can mimic seizures or posterior fossa tumors. Electroencephalogram (EEG) or neuroimaging may be necessary to exclude these disorders. The EEG is usually normal in patients with benign paroxysmal torticollis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of benign paroxysmal torticollis is made with careful attention to the history of the episodes and to the details of the clinical presentation. Often, it is useful to have photographic or video recordings of the attacks (made by the parents). Neurologic consultation may also be useful in the initial stages of evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=see_link\">",
"     \"Clinical and laboratory diagnosis of seizures in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dystonic reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torticollis can occur as part of a dystonic reaction to certain medications, including phenothiazines,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    . A dystonic reaction is an acute spasm of muscle groups characterized by fixed upper gaze, neck twisting, grimace, clenched jaw, and difficulty in speech. It is often painful and can be frightening to the patient. Dystonic reactions that are drug-induced can be treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=see_link&amp;anchor=H13#H13\">",
"     \"First generation (Typical) antipsychotic medication poisoning\", section on 'Acute extrapyramidal syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sandifer syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sandifer syndrome is the term used to describe gastroesophageal reflux with torsion spasms of the neck and abnormal posturing. The torticollis in these patients, similar to those with benign paroxysmal torticollis, occurs intermittently and alternates direction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/40\">",
"     40",
"    </a>",
"    ]. Additional symptoms and complications of gastroesophageal reflux may or may not be present. These include regurgitation, anorexia, hematemesis, irritability, anemia, failure to thrive, asthma, chronic cough, or hoarseness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .) Antireflux therapy is usually effective in treating the dystonic posturing and torticollis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare causes of acquired torticollis include intervertebral disk calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/43\">",
"     43",
"    </a>",
"    ], benign tumors of the cervical spine (osteoid osteoma), bony abnormalities of the cervical spine (eg, occipitocervical synostosis), spondylitis, arterio-venous (AV) malformation, and brain tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/26,44-49\">",
"     26,44-49",
"    </a>",
"    ]. Some of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=see_link\">",
"     \"Back pain in children and adolescents: Overview of causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of acquired torticollis (",
"    <a class=\"graphic graphic_table graphicRef76604 \" href=\"UTD.htm?18/19/18749\">",
"     table 1",
"    </a>",
"    ) is similar to that of congenital torticollis: the head is tilted toward the shortened SCM and the chin rotated toward the opposite side. In contrast to congenital torticollis, the child is usually older, and the onset of torticollis more acute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation of a child with torticollis is to determine whether the child requires immediate intervention. Acute traumatic torticollis should be treated with great caution. The potential for permanent neurologic damage from a spinal cord injury warrants immediate cervical spine immobilization and thorough neurologic examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urgent evaluation also is necessary in children with torticollis and stridor or drooling because these symptoms may indicate a retro- or parapharyngeal abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history helps to narrow the broad differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef76604 \" href=\"UTD.htm?18/19/18749\">",
"     table 1",
"    </a>",
"    ). Important questions to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How old is the child?",
"     </li>",
"     <li>",
"      When did the torticollis develop?",
"     </li>",
"     <li>",
"      How long has the torticollis been present?",
"     </li>",
"     <li>",
"      Was the onset acute or insidious?",
"     </li>",
"     <li>",
"      Is there a history of trauma?",
"     </li>",
"     <li>",
"      Is there a history of fever?",
"     </li>",
"     <li>",
"      Is there a recent history of infection in the head or neck?",
"     </li>",
"     <li>",
"      Is there a recent history of surgery in the head or neck?",
"     </li>",
"     <li>",
"      Are there associated symptoms?",
"     </li>",
"     <li>",
"      Is there a history of exposure to medications or drugs?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should be directed towards verifying the diagnosis of torticollis and identifying possible treatable causes (eg, lymphadenitis, dystonic reaction) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/1,50\">",
"     1,50",
"    </a>",
"    ]. Examination of the head, neck, eyes, upper respiratory tract, and nervous system are particularly important [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of craniofacial asymmetry often indicates congenital or long-standing torticollis.",
"     </li>",
"     <li>",
"      A short neck with a low posterior hair line may indicate a bony cervical spine anomaly (eg, occipitocervical synostosis).",
"     </li>",
"     <li>",
"      The active range of motion of the neck should be assessed; the normal child should be able to flex the chin to the chest, touch the ear to the ipsilateral shoulder, and turn the head 90 degrees to the right or left to touch the chin to the contralateral shoulder. Passive range of motion testing should be performed with caution because of the risk of vertebral subluxation.",
"     </li>",
"     <li>",
"      The presence of ocular torticollis should be evaluated. The corneal light reflex test and the",
"      <span class=\"nowrap\">",
"       cover/uncover",
"      </span>",
"      test should be performed to determine whether the child has strabismus or superior oblique palsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/44/12999?source=see_link&amp;anchor=H10#H10\">",
"       \"Fourth cranial nerve (trochlear nerve) palsy in children\", section on 'Clinical evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation and management of strabismus in children\", section on 'Evaluation'",
"      </a>",
"      .) The fundi should be examined for papilledema, suggestive of an intracranial mass or idiopathic intracranial hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"       \"Elevated intracranial pressure in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"       \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pharynx should be examined for signs of inflammation and retropharyngeal swelling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=see_link\">",
"       \"Retropharyngeal infections in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enlarged lymph nodes in the neck suggest a recent or ongoing head or neck infection.",
"     </li>",
"     <li>",
"      Tenderness of the SCM muscle suggests trauma or myositis.",
"     </li>",
"     <li>",
"      Point tenderness over the cervical spine may indicate underlying fracture, subluxation, or osteomyelitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The neurologic examination should include testing for weakness and sensory deficits, ataxia, and an evaluation of gait.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modality of imaging for acquired torticollis depends upon the age of the patient and the most likely etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/52\">",
"     52",
"    </a>",
"    ]. Cervical spine radiographs should be obtained in all patients who have persistent torticollis, findings suggestive of vertebral involvement, or severe pain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/1\">",
"     1",
"    </a>",
"    ]. Computed tomography (CT) and magnetic resonance imaging (MRI) are helpful in determining the presence and extent of specific lesions and ruling out atlantoaxial rotatory subluxation if plain radiographs are inconclusive or not obtainable [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Patients who have neurologic deficits should undergo computed tomography (CT) or magnetic resonance imaging (MRI) of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/1\">",
"     1",
"    </a>",
"    ]. Ultrasonography or CT imaging of the neck may be helpful in the patient with suspected retropharyngeal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acquired torticollis depends upon the underlying cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emergent conditions such as vertebral subluxation, spinal epidural hematoma, or retropharyngeal abscess require immediate subspecialty consultation and treatment.",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) and a cervical collar (soft or rigid) may relieve the pain and discomfort related to musculoskeletal injury-related torticollis.",
"     </li>",
"     <li>",
"      NSAIDs also are a reasonable first line therapy for children with muscular torticollis.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"       Diazepam",
"      </a>",
"      or muscle relaxants may be tried in children who do not respond to NSAIDS. Botulinum A toxin injection has been shown to be effective in treatment of spasmodic torticollis in adults, but there is little evidence to support its use in children [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/57-60\">",
"       57-60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibiotic therapy is indicated in children who have lymphadenitis or other infectious processes as the underlying cause.",
"     </li>",
"     <li>",
"      Treatment for atlantoaxial subluxation depends upon the severity and duration of the abnormality. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Atlantoaxial rotary subluxation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Torticollis related to strabismus may respond to treatment of the underlying disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/44/12999?source=see_link&amp;anchor=H16#H16\">",
"       \"Fourth cranial nerve (trochlear nerve) palsy in children\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H18#H18\">",
"       \"Evaluation and management of strabismus in children\", section on 'Overview of management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dystonic reactions that are drug-induced can be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"       diazepam",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Antireflux therapy is indicated in children who have gastroesophageal reflux as the primary cause of torticollis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8616/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link\">",
"       \"Management of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most children will have minor muscle injury or muscular inflammation as the cause of their torticollis. These patients typically will have resolution of symptoms in a few days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/41/29329?source=see_link\">",
"       \"Patient information: Torticollis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1691376\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Torticollis, also called wryneck, is a common complaint in children and may be congenital or acquired. Facial asymmetry is often present in children who have congenital torticollis, but rarely in those with acquired torticollis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injury or inflammation from a variety of conditions can cause spasm of cervical muscles or irritation of cervical nerves, resulting in torticollis. Underlying conditions range in severity from benign to potentially life-threatening (",
"      <a class=\"graphic graphic_table graphicRef76604 \" href=\"UTD.htm?18/19/18749\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      With acquired torticollis, the head is tilted toward the shortened SCM and the chin rotated toward the opposite side. In contrast to congenital torticollis, the child is usually older, and the onset of torticollis more acute. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      History, physical examination, and cervical spine imaging will determine the etiology for acute acquired torticollis in most patients. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of acquired torticollis depends upon the underlying cause. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute traumatic torticollis warrant immediate cervical spine immobilization and thorough neurologic examination to assess for a spinal cord injury. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with torticollis and stridor or drooling need urgent evaluation for a serious infectious cause such as retropharyngeal abscess. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children will have minor muscle injury or muscular inflammation as the cause of their torticollis. These patients will have resolution of symptoms in a few days and are treated with nonsteroidal antiinflammatory drugs and a cervical collar (soft or rigid) for comfort. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ozuah, P. Torticollis. In: Primary Pediatric Care, 4th, Hoekelman, RA (Eds), Mosby, St. Louis 2001. p.1282.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/2\">",
"      Soundappan SV, Darwish B, Chaseling R. Traumatic spinal epidural hematoma-unusual cause of torticollis in a child. Pediatr Emerg Care 2005; 21:847.",
"     </a>",
"    </li>",
"    <li>",
"     Torticollis. In: Signs and Symptoms in Pediatrics, 3rd, Tunnessen WW, Roberts KB (Eds), Lippincot Williams &amp; Wilkins, Philadelphia 1999. p.353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/4\">",
"      Bredenkamp JK, Maceri DR. Inflammatory torticollis in children. Arch Otolaryngol Head Neck Surg 1990; 116:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/5\">",
"      Harries PG. Retropharyngeal abscess and acute torticollis. J Laryngol Otol 1997; 111:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/6\">",
"      Visudhiphan P, Chiemchanya S, Somburanasin R, Dheandhanoo D. Torticollis as the presenting sign in cervical spine infection and tumor. Clin Pediatr (Phila) 1982; 21:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/7\">",
"      Ballock RT, Song KM. The prevalence of nonmuscular causes of torticollis in children. J Pediatr Orthop 1996; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/8\">",
"      Mu&ntilde;iz AE, Belfer RA. Atlantoaxial rotary subluxation in children. Pediatr Emerg Care 1999; 15:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/9\">",
"      Brisson P, Patel H, Scorpio R, Feins N. Rotary atlanto-axial subluxation with torticollis following central-venous catheter insertion. Pediatr Surg Int 2000; 16:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/10\">",
"      Gourin CG, Kaper B, Abdu WA, Donegan JO. Nontraumatic atlanto-axial subluxation after retropharyngeal cellulitis: Grisel's syndrome. Am J Otolaryngol 2002; 23:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/11\">",
"      Berry DS, Moriarty RA. Atlantoaxial subluxation related to pharyngitis: Grisel's syndrome. Clin Pediatr (Phila) 1999; 38:673.",
"     </a>",
"    </li>",
"    <li>",
"     Torticollis. In: Essentials of Musculoskeletal Care, 2nd, Greene WB (Ed), American Academy of Orthopedic Surgeons, Rosement 2001. p.719.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/13\">",
"      Tom LW, Rossiter JL, Sutton LN, et al. Torticollis in children. Otolaryngol Head Neck Surg 1991; 105:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/14\">",
"      Atlantoaxial instability in Down syndrome: subject review. American Academy of Pediatrics Committee on Sports Medicine and Fitness. Pediatrics 1995; 96:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/15\">",
"      Pueschel SM, Scola FH. Atlantoaxial instability in individuals with Down syndrome: epidemiologic, radiographic, and clinical studies. Pediatrics 1987; 80:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/16\">",
"      Hall DE, Boydston W. Pediatric neck injuries. Pediatr Rev 1999; 20:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/17\">",
"      Herman MJ, Pizzutillo PD. Cervical spine disorders in children. Orthop Clin North Am 1999; 30:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/18\">",
"      Ruge JR, Sinson GP, McLone DG, Cerullo LJ. Pediatric spinal injury: the very young. J Neurosurg 1988; 68:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/19\">",
"      Herzka A, Sponseller PD, Pyeritz RE. Atlantoaxial rotatory subluxation in patients with Marfan syndrome. A report of three cases. Spine (Phila Pa 1976) 2000; 25:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/20\">",
"      Li MF, Chiu PC, Weng MJ, Lai PH. Atlantoaxial instability and cervical cord compression in Morquio syndrome. Arch Neurol 2010; 67:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/21\">",
"      Msall ME, Reese ME, DiGaudio K, et al. Symptomatic atlantoaxial instability associated with medical and rehabilitative procedures in children with Down syndrome. Pediatrics 1990; 85:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/22\">",
"      Chaudhry V, Sturgeon C, Gates AJ, Myers G. Symptomatic atlantoaxial dislocation in Down's syndrome. Ann Neurol 1987; 21:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/23\">",
"      Godard J, Jacquet G, Bonneville JF, et al. [Torticollis and C1-C2 rotation subluxation. Apropos of a case. The value of a dynamic scanner and of a 3-dimensional scanner]. J Neuroradiol 1994; 21:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/24\">",
"      Phillips WA, Hensinger RN. The management of rotatory atlanto-axial subluxation in children. J Bone Joint Surg Am 1989; 71:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/25\">",
"      Subach BR, McLaughlin MR, Albright AL, Pollack IF. Current management of pediatric atlantoaxial rotatory subluxation. Spine (Phila Pa 1976) 1998; 23:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/26\">",
"      Epps HR, Salter RB. Orthopedic conditions of the cervical spine and shoulder. Pediatr Clin North Am 1996; 43:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/27\">",
"      Fielding JW, Hawkins RJ. Atlanto-axial rotatory fixation. (Fixed rotatory subluxation of the atlanto-axial joint). J Bone Joint Surg Am 1977; 59:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/28\">",
"      Craig FW, Schunk JE. Retropharyngeal abscess in children: clinical presentation, utility of imaging, and current management. Pediatrics 2003; 111:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/29\">",
"      Young TL, Weis JR, Summers CG, Egbert JE. The association of strabismus, amblyopia, and refractive errors in spasmus nutans. Ophthalmology 1997; 104:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/30\">",
"      Drigo P, Carli G, Laverda AM. Benign paroxysmal torticollis of infancy. Brain Dev 2000; 22:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/31\">",
"      Hanukoglu A, Somekh E, Fried D. Benign paroxysmal torticollis in infancy. Clin Pediatr (Phila) 1984; 23:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/32\">",
"      Al-Twaijri WA, Shevell MI. Pediatric migraine equivalents: occurrence and clinical features in practice. Pediatr Neurol 2002; 26:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/33\">",
"      Deonna T, Martin D. Benign paroxysmal torticollis in infancy. Arch Dis Child 1981; 56:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/34\">",
"      Kimura S, Nezu A. Electromyographic study in an infant with benign paroxysmal torticollis. Pediatr Neurol 1998; 19:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/35\">",
"      Del Cuore F. [Benign paroxysmal torticollis in childhood]. Pediatr Med Chir 1997; 19:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/36\">",
"      Cataltepe SU, Barron TF. Benign paroxysmal torticollis presenting as \"seizures\" in infancy. Clin Pediatr (Phila) 1993; 32:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/37\">",
"      Balslev T, Flarup M, Ostergaard JR, Haslam RH. [Benign paroxysmal torticollis. Recurrent involuntary twisting of the head in infants and young children]. Ugeskr Laeger 1998; 160:5365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/38\">",
"      Chaves-Carballo E. Paroxysmal torticollis. Semin Pediatr Neurol 1996; 3:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/39\">",
"      Bratt HD, Menelaus MB. Benign paroxysmal torticollis of infancy. J Bone Joint Surg Br 1992; 74:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/40\">",
"      Murphy WJ, Gellis SS. Torticollis with hiatus hernia in infancy. Sandifer syndrome. Am J Dis Child 1977; 131:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/41\">",
"      Deskin RW. Sandifer syndrome: a cause of torticollis in infancy. Int J Pediatr Otorhinolaryngol 1995; 32:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/42\">",
"      Werlin SL, D'Souza BJ, Hogan WJ, et al. Sandifer syndrome: an unappreciated clinical entity. Dev Med Child Neurol 1980; 22:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/43\">",
"      Causey AL, Evans OB, Lewis-Abney K. Intervertebral disk calcification: an unusual cause of acquired torticollis in childhood. Pediatr Emerg Care 1996; 12:356.",
"     </a>",
"    </li>",
"    <li>",
"     The neck. In: Pediatric Diagnosis: Interpretation of Symptoms and Signs in Children and Adolescents, 6th, Green M (Ed), WB Saunders, Philadelphia 1998. p.63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/45\">",
"      Caputo AR, Mickey KJ, Guo S, et al. The sit-up test: an alternate clinical test for evaluating pediatric torticollis. Pediatrics 1992; 90:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/46\">",
"      Oliveira T, Barbosa C, Neves E, et al. [Cervical spondylodiscitis in an infant]. An Esp Pediatr 2000; 52:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/47\">",
"      Mutsaers P, Fick M, Pl&ouml;tz FB. Acquired torticollis as the only initially presenting symptom in a child with a brainstem glioma. Eur J Pediatr 2007; 166:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/48\">",
"      Gupta AK, Roy DR, Conlan ES, Crawford AH. Torticollis secondary to posterior fossa tumors. J Pediatr Orthop 1996; 16:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/49\">",
"      Turgut M, Akalan N, Bertan V, et al. Acquired torticollis as the only presenting symptom in children with posterior fossa tumors. Childs Nerv Syst 1995; 11:86.",
"     </a>",
"    </li>",
"    <li>",
"     Staheli LT. Spine and neck. In: Fundamentals of Pediatric Orthopedics, 2nd, Lippincott Raven, Philadelphia 1998. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/51\">",
"      Straussberg R, Harel L, Amir J. Pseudotumor cerebri manifesting as stiff neck and torticollis. Pediatr Neurol 2002; 26:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/52\">",
"      Haque S, Bilal Shafi BB, Kaleem M. Imaging of torticollis in children. Radiographics 2012; 32:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/53\">",
"      Lin JN, Chou ML. Ultrasonographic study of the sternocleidomastoid muscle in the management of congenital muscular torticollis. J Pediatr Surg 1997; 32:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/54\">",
"      Entel RJ, Carolan FJ. Congenital muscular torticollis: magnetic resonance imaging and ultrasound diagnosis. J Neuroimaging 1997; 7:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/55\">",
"      Pang D. Atlantoaxial rotatory fixation. Neurosurgery 2010; 66:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/56\">",
"      Lazor JB, Cunningham MJ, Eavey RD, Weber AL. Comparison of computed tomography and surgical findings in deep neck infections. Otolaryngol Head Neck Surg 1994; 111:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/57\">",
"      Sloop RR, Cole D, Patel MC. Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals. Mov Disord 2001; 16:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/58\">",
"      Boghen D, Flanders M. Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. Eur Neurol 1993; 33:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/59\">",
"      Finsterer J, Fuchs I, Mamoli B. Quantitative electromyography-guided botulinum toxin treatment of cervical dystonia. Clin Neuropharmacol 1997; 20:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8616/abstract/60\">",
"      Racette BA, McGee-Minnich L, Perlmutter JS. Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clin Neuropharmacol 1999; 22:337.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6462 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8616=[""].join("\n");
var outline_f8_26_8616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1691376\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Atlantoaxial rotary subluxation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Retropharyngeal abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ocular torticollis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Spasmus nutans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Benign paroxysmal torticollis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dystonic reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sandifer syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1691376\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6462\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6462|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/5/3153\" title=\"diagnostic image 1\">",
"      Grisel syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/46/12015\" title=\"diagnostic image 2\">",
"      Retropharyngeal abscess CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6462|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/19/18749\" title=\"table 1\">",
"      Differential diagnosis of  acquired torticollis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/4/14409?source=related_link\">",
"      Clinical and laboratory diagnosis of seizures in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43798?source=related_link\">",
"      Congenital muscular torticollis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=related_link\">",
"      First generation (Typical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/44/12999?source=related_link\">",
"      Fourth cranial nerve (trochlear nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/41/29329?source=related_link\">",
"      Patient information: Torticollis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1034?source=related_link\">",
"      Pendular nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43046?source=related_link\">",
"      Sixth cranial nerve (abducens nerve) palsy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_26_8617="Sotalol: Pediatric drug information";
var content_f8_26_8617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sotalol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"    see \"Sotalol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/22/33125?source=see_link\">",
"    see \"Sotalol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F222498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betapace AF&reg;;",
"     </li>",
"     <li>",
"      Betapace&reg;;",
"     </li>",
"     <li>",
"      Sorine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F222499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sotalol&reg;;",
"     </li>",
"     <li>",
"      CO Sotalol;",
"     </li>",
"     <li>",
"      Dom-Sotalol;",
"     </li>",
"     <li>",
"      Med-Sotalol;",
"     </li>",
"     <li>",
"      Mylan-Sotalol;",
"     </li>",
"     <li>",
"      Novo-Sotalol;",
"     </li>",
"     <li>",
"      Nu-Sotalol;",
"     </li>",
"     <li>",
"      PHL-Sotalol;",
"     </li>",
"     <li>",
"      PMS-Sotalol;",
"     </li>",
"     <li>",
"      PRO-Sotalol;",
"     </li>",
"     <li>",
"      ratio-Sotalol;",
"     </li>",
"     <li>",
"      Rhoxal-sotalol;",
"     </li>",
"     <li>",
"      Riva-Sotalol;",
"     </li>",
"     <li>",
"      Rylosol;",
"     </li>",
"     <li>",
"      Sandoz-Sotalol;",
"     </li>",
"     <li>",
"      ZYM-Sotalol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class II",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class III",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     must be determined prior to initiation. Dosage must be adjusted to individual response and tolerance; doses should be initiated or increased in a hospital facility that can provide continuous ECG monitoring, recognition and treatment of life-threatening arrhythmias, and CPR.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer's dosing recommendations are based on doses per m",
"     <sup>",
"      2",
"     </sup>",
"     (that are equivalent to the doses recommended in adults) and on pediatric pharmacokinetic and pharmacodynamic studies (Saul, 2001; Saul, 2001a). BSA, rather than body weight, better predicted apparent clearance of sotalol; however, for a given dose per m",
"     <sup>",
"      2",
"     </sup>",
"     , a larger drug exposure (larger AUC) and greater pharmacologic effects were observed in smaller subjects (ie, those with BSA &lt;0.33 m",
"     <sup>",
"      2",
"     </sup>",
"     versus those with BSA &ge;0.33 m",
"     <sup>",
"      2",
"     </sup>",
"     ). For infants and children &le;2 years of age, the manufacturer recommends a dosage reduction based on an age factor determined from a graph (see below).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's recommendations:",
"     <b>",
"      Note:",
"     </b>",
"     Use with extreme caution if QT",
"     <sub>",
"      c",
"     </sub>",
"     is &gt;500 msec while receiving sotalol; reduce the dose or discontinue drug if QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;550 msec.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The manufacturer recommended pediatric dosage of 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given 3 times/day must be",
"     <b>",
"      REDUCED",
"     </b>",
"     by an age-related factor that is obtained from the graph (see graph). First, obtain the patient's age in months; use the graph to determine where the patient's age (on the logarithmic scale) intersects the age factor curve; read the age factor from the Y-axis; then multiply the age factor by the pediatric dose listed below (ie, the dose for children &gt;2 years); this will result in the proper reduction in dose for age. For example, the age factor for a neonate (PNA: 14 days) is 0.5, so the initial dosage would be (0.5 x 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose) = 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given 3 times daily. Similar calculations should be made for dosage titrations; increase dosage gradually, if needed; allow adequate time between dosage increments to achieve new steady-state and to monitor clinical response, heart rate and QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals; half-life is prolonged with decreasing age (&lt;2 years), so time to reach new steady-state will increase; for example, the time to reach steady-state in a neonate may be &ge;1 week.",
"    </p>",
"    (",
"    <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/57/41880\">",
"     See Age nomogram",
"    </a>",
"    )",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternative dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 2 mg/kg/day divided every 8 hours; if needed, increase dosage gradually by 1-2 mg/kg/day increments; allow at least 3 days between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals (L&auml;er, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proposed required dose: 4 mg/kg/day divided every 8 hours;",
"     <b>",
"      Note:",
"     </b>",
"     It is not necessary to increase to required dosage if desired clinical effect has been achieved at a lower dosage",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"      see \"Sotalol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     must be determined prior to initiation. Dosage must be adjusted to individual response and tolerance; doses should be initiated or increased in a hospital facility that can provide continuous ECG monitoring, recognition and treatment of life-threatening arrhythmias, and CPR:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     Infants and Children: Manufacturer's dosing recommendations are based on doses per m",
"     <sup>",
"      2",
"     </sup>",
"     (that are equivalent to the doses recommended in adults) and on pediatric pharmacokinetic and pharmacodynamic studies (Saul, 2001; Saul, 2001a). BSA, rather than body weight, better predicted apparent clearance of sotalol; however, for a given dose per m",
"     <sup>",
"      2",
"     </sup>",
"     , a larger drug exposure (larger AUC) and greater pharmacologic effects were observed in smaller subjects (ie, those with BSA &lt;0.33 m",
"     <sup>",
"      2",
"     </sup>",
"     versus those with BSA &ge;0.33 m",
"     <sup>",
"      2",
"     </sup>",
"     ). For infants and children &le;2 years of age, the manufacturer recommends a dosage reduction based on an age factor determined from a graph (see below).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's recommendations:",
"     <b>",
"      Note:",
"     </b>",
"     Use with extreme caution if QT",
"     <sub>",
"      c",
"     </sub>",
"     is &gt;500 msec while receiving sotalol; reduce the dose or discontinue drug if QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;550 msec.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children &le;2 years: The manufacturer recommended pediatric dosage of 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose 3 times/day must be",
"     <b>",
"      REDUCED",
"     </b>",
"     using an age-related factor that is obtained from the graph (see graph). First, obtain the patient's age in months; use the graph to determine where the patient's age (on the logarithmic scale) intersects the age factor curve; read the age factor from the Y-axis; then multiply the age factor by the pediatric dose listed below (ie, the dose for children &gt;2 years); this will result in the proper reduction in dose for age. For example, the age factor for an infant 1 month of age is 0.68, so the initial dosage would be (0.68 x 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose) = 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given 3 times daily. Similar calculations should be made for dosage titrations; increase dosage gradually, if needed; allow adequate time between dosage increments to achieve new steady-state and to monitor clinical response, heart rate and QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals; half-life is prolonged with decreasing age (&lt;2 years), so time to reach new steady-state will increase.",
"    </p>",
"    (",
"    <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/57/41880\">",
"     See Age nomogram",
"    </a>",
"    )",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &gt;2 years: Initial: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given 3 times daily; increase dosage gradually if needed; allow at least 36 hours between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals; may increase gradually to a maximum of 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternative pediatric dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 2 mg/kg/day divided every 8 hours; if needed, increase dosage gradually by 1-2 mg/kg/day increments; allow 3 days between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals; maximum: 10 mg/kg/day (if no limiting side effects occur) (Beaufort-Krol, 1997; Colloridi, 1992; L&auml;er, 2005; Maragnes, 1992; Pfammatter, 1995; Pfammatter, 1997; Tipple, 1991); do not exceed adult doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Proposed required doses:",
"     <b>",
"      Note:",
"     </b>",
"     It is not necessary to increase to required dosage if desired clinical effect has been achieved at a lower dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Infants and Children 1 month to 6 years: 6 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Children &gt;6 years: 4 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ventricular arrhythmias (Betapace&reg;, Sorine&reg;, generic) (",
"     <b>",
"      Note:",
"     </b>",
"     Use with extreme caution if QT",
"     <sub>",
"      c",
"     </sub>",
"     is &gt;500 msec while receiving sotalol; reduce the dose or discontinue drug if QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;550 msec): Initial: 80 mg twice daily; increase dosage gradually if needed; allow 3 days between dosage increments to achieve new steady-state and to determine maximum effects on QT interval; may increase gradually to 240-320 mg/day in 2 divided doses; usual effective dose: 160-320 mg/day given in 2-3 divided doses;",
"     <b>",
"      Note:",
"     </b>",
"     Doses as high as 480-640 mg/day may be required in some patients with life-threatening refractory ventricular arrhythmias; however, potential benefit must outweigh increased risk of adverse effects (eg, proarrhythmias).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Atrial fibrillation or atrial flutter (Betapace AF&reg;): [",
"     <b>",
"      Note:",
"     </b>",
"     If baseline QT interval is &gt;450 msec, do not initiate therapy. During initiation and dose titration, if the QT interval is &ge;500 msec, reduce the dose or discontinue the drug. During maintenance therapy, monitor the QT interval regularly; if the QT interval is &ge;520 msec, reduce the dose or discontinue the drug]: Initial: 80 mg twice daily; increase dosage gradually after 3 days, if needed [ie, if frequency of relapses of atrial fibrillation/flutter is not reduced and the dose is tolerated without excessive QT prolongation (ie, if QT interval is &lt;520 msec)]; allow 3 days between dosage increments to achieve new steady-state and to determine maximum effects on QT interval; reduce the dose or discontinue the drug if the QT interval is &ge;500 msec; dose may be increased to 120 mg twice daily (usual effective dose); the dosage may be further increased to 160 mg twice daily if response is inadequate and the dose is tolerated without excessive QT prolongation; maximum dose: 160 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     must be determined prior to initiation. The effects of the initial I.V. dose must be monitored and the dose titrated either upward or downward, if needed, based on clinical effect, QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, or adverse reactions. Doses should be initiated or increased in a hospital facility that can provide continuous ECG monitoring, recognition, and treatment of life-threatening arrhythmias, and CPR:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conversion from oral sotalol to I.V. sotalol:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     80 mg oral equivalent to 75 mg I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     120 mg oral equivalent to 112.5 mg I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     160 mg oral equivalent to 150 mg I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ventricular arrhythmias:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Substitution for oral sotalol: Initial dose: 75 mg infused over 5 hours twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose adjustment: If the frequency of relapse does not reduce and excessive QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation does not occur, may increase to 112.5 mg twice daily. For ventricular arrhythmias, may increase dose every 3 days in increments of 75 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose range: Usual therapeutic dose: 75-150 mg twice daily; maximum dose: 300 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodynamically stable monomorphic VT, ongoing: 1.5 mg/kg over 5 minutes (ACLS, 2010);",
"     <b>",
"      Note:",
"     </b>",
"     One clinical trial employed standard dose of 100 mg (Ho, 1994).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atrial fibrillation or atrial flutter:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Substitution for oral sotalol: Initial dose: 75 mg infused over 5 hours twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose adjustment: If the frequency of relapse does not reduce and excessive QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation does not occur, may increase to 112.5 mg twice daily. For ventricular arrhythmias, may increase dose every 3 days in increments of 75 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dose range: Usual therapeutic dose: 112.5 mg twice daily; maximum dose: 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Dosing in children with renal impairment has not been investigated; use lower doses or increased dosing intervals; closely monitor clinical response, heart rate and QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; allow adequate time between dosage increments to achieve new steady-state, since half-life will be prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Administer the initial dose (ie, 80 mg) and subsequent doses at the following intervals:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ventricular arrhythmias (Betapace&reg;, Sorine&reg;, generic):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: Administer every 36-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Individualize dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Atrial fibrillation/flutter (Betapace AF&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-60 mL/minute: Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: Use is contraindicated (per product labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The manufacturer of the injectable formulation recommends adjustment similar to that used for Betapace AF&reg;; however, the injectable formulation may be used for either indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to the prolonged half-life in patients with renal dysfunction, allow at least 5-6 doses (at the above recommended interval) between dosage increments to achieve a new steady-state and to monitor QT intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Not needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 15 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 80 mg [atrial fibrillation], 80 mg, 120 mg [atrial fibrillation], 120 mg, 160 mg [atrial fibrillation], 160 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betapace AF&reg;: 80 mg, 120 mg, 160 mg [scored; atrial fibrillation]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betapace&reg;: 80 mg, 120 mg, 160 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sorine&reg;: 80 mg, 120 mg, 160 mg, 240 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered without regard to meals, but should be administered at the same time each day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Substitution for oral: Dilute in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or LR to final concentration of 0.75-1.5 mg/mL and infuse over 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hemodynamically stable monomorphic VT: Administer I.V. push over 5 minutes; use with caution due to increased risk of adverse events (eg, bradycardia, hypotension, torsades de pointes) (ACLS, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9830565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or lactated Ringer's.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets and injection: Store at controlled room temperature 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Dispense in tight, light-resistant container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Protect from light; do not freeze. Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or lactated ringers.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Betapace&reg;, Sorine&reg;, generic: Treatment of life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia) (Betapace&reg;: FDA approved in ages &ge;3 days and adults; Sorine&reg;, generic: FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Betapace AF&reg;: Maintenance of normal sinus rhythm in patients who have highly symptomatic atrial fibrillation and atrial flutter, but who are currently in normal sinus rhythm [not usually for use in patients with paroxysmal atrial fibrillation/flutter that is easily reversed (eg, by Valsalva maneuver)] (FDA approved in ages &ge;3 days and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not substitute Betapace AF&reg; for other products (and vice versa); significant differences in FDA approved labeling exist [eg, dosage and administration, safety information and patient package insert (Betapace AF&reg; labeling contains a patient package insert specific for atrial fibrillation/flutter)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Substitution for oral sotalol in those who are unable to take sotalol orally (FDA approved in ages &ge;3 years and adults); used in adult ACLS algorithm for hemodynamically stable monomorphic ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F222546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sotalol may be confused with Stadol, Sudafed&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Betapace&reg; may be confused with Betapace AF&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F222544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     No clinical experience with I.V. sotalol; however, since exposure is similar between I.V. and oral sotalol, adverse reactions are expected to be similar.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Abnormal ECG, bradycardia, chest pain, CHF, edema, hypotension, palpitation, peripheral vascular disorders, proarrhythmia, QT",
"     <sub>",
"      c",
"     </sub>",
"     interval prolongation (dose related), syncope, torsade de pointes (dose related), ventricular tachycardia worsened",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, fatigue, headache, lightheadedness, mental confusion, sleep problems",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased sexual ability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, flatulence, nausea, stomach discomfort, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, extremity pain, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual problems",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, upper respiratory problems",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, bronchiolitis obliterans with organized pneumonia (BOOP), cold extremities, diaphoresis, eosinophilia, increased serum transaminases, leukocytoclastic vasculitis, leukopenia, paralysis, phlebitis, photosensitivity reaction, pruritus, pulmonary edema, Raynaud's phenomenon, red crusted skin, retroperitoneal fibrosis, skin necrosis after extravasation, thrombocytopenia, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sotalol or any component; sinus bradycardia; second or third degree AV heart block (except in patients with a functioning artificial pacemaker); congenital or acquired long QT syndromes; uncontrolled heart failure; cardiogenic shock; asthma",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Additional contraindications: Betapace AF&reg; and the injectable formulation: Baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval &gt;450 msec; bronchospastic conditions; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute; serum potassium &lt;4 mEq/L; sick sinus syndrome (except in patients with a functioning artificial pacemaker)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients receiving calcium channel blockers.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiation, reinitiation, and dosage increases of sotalol must occur in a facility that can provide continuous ECG monitoring, recognition and treatment of life-threatening arrhythmias, and CPR",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Patients must be monitored with continuous ECG for a minimum of 3 days (on their maintenance dose). Use with caution and adjust the dose in patients with renal impairment; creatinine clearance must be calculated prior to dosing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause serious and life-threatening proarrhythmias [may cause or worsen ventricular arrhythmias (eg, sustained ventricular tachycardia, torsade de pointes, ventricular fibrillation)]",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk factors for torsade de pointes include: Higher sotalol doses, presence of sustained VT, female gender, excessive prolongation of the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval, history of heart failure or cardiomegaly, decreased renal function, hypokalemia, hypomagnesemia, and bradycardia; monitor ECG for proarrhythmic effects; adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation; correct electrolyte imbalances (especially hypokalemia and hypomagnesemia) before initiating sotalol. Do not initiate I.V. therapy if baseline QT",
"     <sub>",
"      c",
"     </sub>",
"     interval is &gt;450 msec; if QT",
"     <sub>",
"      c",
"     </sub>",
"     exceeds 500 msec during therapy, reduce the dose, prolong the infusion duration, or discontinue use",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Bradycardia, heart block, or hypotension may occur. Use oral formulation only with extreme caution in patients with sick sinus syndrome; do not use I.V. product in patients with sick sinus syndrome unless functioning artificial pacemaker is present. May cause or worsen heart failure (use with caution in patients with compensated heart failure); use with caution and titrate dose carefully within the first 2 weeks post-MI (experience is limited); use with caution in patients with peripheral vascular disease (may aggravate arterial insufficiency). Concomitant use with other drugs that prolong the QT interval (eg, Class I and Class III antiarrhythmics, phenothiazines, tricyclic antidepressants, and certain oral macrolide and quinolone antibiotics) or prolong refractoriness (eg, disopyramide, quinidine, procainamide, and amiodarone) is not recommended; Class I or Class III antiarrhythmic agents should be withheld for at least three half-lives prior to starting sotalol.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Exacerbation of angina, arrhythmias, and in some cases MI may occur following abrupt discontinuation of beta-blockers; avoid abrupt discontinuation, wean slowly, monitor for signs and symptoms of ischemia. Beta-blockers should generally be avoided in patients with bronchospastic disease; if administered, use the lowest possible dose and monitor patients carefully. Patients receiving beta-blockers, who have a history of anaphylactic reactions, may be more reactive to a repeated allergen challenge and may not be responsive to the usual epinephrine doses used to treat an allergic reaction. Beta-blockers may block hypoglycemia-induced tachycardia and blood pressure changes; use with caution in patients with diabetes mellitus. May mask signs of thyrotoxicosis. Use caution with anesthetic agents that decrease myocardial function.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F222462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases oral absorption by &sim;20% compared to fasting",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F222480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies sotalol as pregnancy category B. Sotalol crosses the placenta and is found in amniotic fluid. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother; however, sotalol is currently not recommended for the initial treatment of hypertension in pregnancy. Because sotalol crosses the placenta in concentrations similar to the maternal serum, it has been used for the treatment of fetal atrial flutter or fetal supraventricular tachycardia without hydrops. The clearance of sotalol is increased during the third trimester of pregnancy, but other pharmacokinetic parameters do not significantly differ from nonpregnant values.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous ECG for a minimum of 3 days with initiation of therapy or dosage increase, QT interval, heart rate, renal function, serum potassium, and magnesium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Betapace AF&reg;: In addition, during initiation and dosage titration, monitor the QT interval 2-4 hours after each dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injectable formulation: Monitor QT interval after completion of each infusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Beta-blocker with both class II antiarrhythmic (beta-adrenergic blockade) and class III antiarrhythmic (prolongation of the cardiac action potential duration) properties; does not possess partial agonist or membrane stabilizing activity. Class II effects: Nonselective beta-blockade; competitively blocks response to beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic stimulation; decreases heart rate and AV nodal conduction; increases AV nodal refractoriness. Class III effects: Prolongs atrial and ventricular monophasic action potentials; prolongs the effective refractory period of atrial muscle, ventricular muscle, and AV accessory pathways (if present) in both antegrade and retrograde directions. Significant beta-blocking effects may be seen at lower doses (children: &ge;90 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; adults: 25 mg); class III electrophysiologic effects are seen at higher doses (children: 210 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; adults: &ge;160 mg/day). Sotalol is available as a racemic mixture; both isomers (d- and l-sotalol) have similar class III antiarrhythmic effects; the l-isomer is responsible for almost all of the beta-adrenergic blocking activity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F12604930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Oral: Rapid: 1-2 hours; when administered I.V. for ongoing VT over 5 minutes, onset of action is ~5-10 minutes (Ho, 1994)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Poor penetration across blood-brain barrier; distributes into breast milk; breast milk to plasma ratio: 2.2-8.8 (mean: 5.4) (O'Hare, 1980)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Sotalol is not protein bound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Sotalol is not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 90% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (mean):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates &le;1 month: 8.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and children &gt;1 month to 24 months: 7.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;2 years to &lt;7 years: 9.1 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 7-12 years: 9.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with renal failure (anuric): Up to 69 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4 days to 12 years: Mean: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily as unchanged drug via the kidney",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance (apparent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates &le;1 month: 11 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and children &gt;1 month to 24 months: 32 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;2 years to &lt;7 years: 63 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 7-12 years: 95 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Partially removed by hemodialysis; partial rebound in serum concentrations may occur following dialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/22/33125?source=see_link\">",
"      see \"Sotalol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take sotalol every day as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, do not double the next dose, take the next dose at the usual time. Avoid abrupt discontinuation; if sotalol is to be discontinued, physician will advise how to slowly taper the dose over 1-2 weeks. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Regular cardiac checkups, ECGs, and blood tests will be needed while taking this medication. Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; do not start new medications without checking with your physician and pharmacist; tell your dentist and physician that you are taking sotalol before you have dental surgery or an operation (sotalol may interact with certain anesthetic agents). Report fast heartbeats, dizziness, or fainting immediately to your physician or go to an emergency room (these may be signs of an abnormal heartbeat); report severe diarrhea, unusual sweating, vomiting, increased thirst, or decreased appetite immediately to your physician (these may be things that make an abnormal heartbeat more likely to occur); report chest pain, fast heartbeat, swelling of ankles or legs, difficulty breathing or unusual cough to your physician (these may be serious side effects of the medication).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Betapace AF&reg;: Do not discharge patients from the hospital within 12 hours of electrical or pharmacological conversion from atrial fibrillation/flutter to normal sinus rhythm.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F222474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 5 mg/mL sotalol hydrochloride syrup may be made with Betapace&reg; or Betapace AF&reg; tablets and Simple Syrup containing sodium benzoate 0.1% (Syrup, NF). Place 120 mL Syrup, NF in a 6-ounce amber plastic (polyethylene terephthalate) prescription bottle; add five Betapace&reg; or Betapace AF&reg; 120 mg tablets and shake the bottle to wet the tablets. Allow tablets to hydrate for at least 2 hours, then shake intermittently over &ge;2 hours until the tablets are completely disintegrated; a dispersion of fine particles (water-insoluble inactive ingredients) in syrup should be obtained.",
"     <b>",
"      Note:",
"     </b>",
"     To simplify the disintegration process, tablets can hydrate overnight; tablets may also be crushed, carefully transferred into the bottle and shaken well until a dispersion of fine particles in syrup is obtained. Label \"shake well\". Stable for 3 months at controlled room temperature (15&deg;C to 30&deg;C [59&deg;F to 86&deg;F]) and ambient humidity.",
"    </p>",
"    <div class=\"reference\">",
"     Betapace&reg; prescribing information, Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ, 2007.",
"    </div>",
"    <div class=\"reference\">",
"     Betapace AF&reg; prescribing information, Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ, 2009.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Beaufort-Krol GC and Bink-Boelkens MT, &ldquo;Effectiveness of Sotalol for Atrial Flutter in Children After Surgery for Congenital Heart Disease,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1997, 79(1):92-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/9024748/pubmed\" id=\"9024748\" target=\"_blank\">",
"        9024748",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colloridi V, Perri C, Ventriglia F, et al, &ldquo;Oral Sotalol in Pediatric Atrial Ectopic Tachycardia,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1992, 123(1):254-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/1729843 /pubmed\" id=\"1729843 \" target=\"_blank\">",
"        1729843",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, \"Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):S640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ho DS, Zecchin RP, Richards DA, et al, \"Double-Blind Trial of Lignocaine Versus Sotalol for Acute Termination of Spontaneous Sustained Ventricular Tachycardia,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 344(8914):18-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/7912296/pubmed\" id=\"7912296\" target=\"_blank\">",
"        7912296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      L&auml;er S, Elshoff JP, Meibohm B, et al, \"Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol Based on Population Pharmacokinetics and Pharmacodynamics in Children With Supraventricular Tachycardia,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 46(7):1322-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/16198851/pubmed\" id=\"16198851\" target=\"_blank\">",
"        16198851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maragnes P, Tipple M, and Fournier A, &ldquo;Effectiveness of Oral Sotalol for Treatment of Pediatric Arrhythmias,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1992, 69(8):751-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/1546649/pubmed\" id=\"1546649\" target=\"_blank\">",
"        1546649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, \"Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):S729-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/20956224/pubmed\" id=\"20956224\" target=\"_blank\">",
"        20956224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Hare MF, Murnaghan GA, Russell CJ, et al, &ldquo;Sotalol as a Hypotensive Agent in Pregnancy,&rdquo;",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1980, 87(9):814-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/7426541/pubmed\" id=\"7426541\" target=\"_blank\">",
"        7426541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfammatter JP and Paul T, &ldquo;New Antiarrhythmic Drug in Pediatric Use: Sotalol,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1997, 18(1):28-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/8960489 /pubmed\" id=\"8960489 \" target=\"_blank\">",
"        8960489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfammatter JP, Paul T, Lehmann C, et al, &ldquo;Efficacy and Proarrhythmia of Oral Sotalol in Pediatric Patients,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1995, 26(4):1002-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/7560592 /pubmed\" id=\"7560592 \" target=\"_blank\">",
"        7560592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saul JP, Ross B, Schaffer MS, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Sotalol in a Pediatric Population With Supraventricular and Ventricular Tachyarrhythmia,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2001, 69(3):145-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/11240979/pubmed\" id=\"11240979\" target=\"_blank\">",
"        11240979",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saul JP, Schaffer MS, Karpawich PP, et al, &ldquo;Single-Dose Pharmacokinetics of Sotalol in a Pediatric Population With Supraventricular and/or Ventricular Tachyarrhythmia,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41(1):35-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/11144992/pubmed\" id=\"11144992\" target=\"_blank\">",
"        11144992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tanel RE, Walsh EP, Lulu JA, et al, &ldquo;Sotalol for Refractory Arrhythmias in Pediatric and Young Adult Patients: Initial Efficacy and Long-Term Outcome,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1995, 130(4):791-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/ 7572588 /pubmed\" id=\" 7572588 \" target=\"_blank\">",
"        7572588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tipple M and Sandor G, &ldquo;Efficacy and Safety of Oral Sotalol in Early Infancy,&rdquo;",
"      <i>",
"       Pacing Clin Electrophysiol",
"      </i>",
"      , 1991, 14(11 Pt 2):2062-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/26/8617/abstract-text/ 1721225 /pubmed\" id=\" 1721225 \" target=\"_blank\">",
"        1721225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12802 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.22.229.50-9649136F8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8617=[""].join("\n");
var outline_f8_26_8617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709415\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222498\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055457\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445105\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055448\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222468\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222453\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055461\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9830565\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055452\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055460\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222546\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222544\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055465\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055447\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055446\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300075\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222462\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055468\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222464\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222480\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055456\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055445\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12604930\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055464\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055454\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055466\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222474\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12802|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/57/41880\" title=\"Age nomogram\">",
"      Age nomogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=related_link\">",
"      Sotalol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/22/33125?source=related_link\">",
"      Sotalol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_26_8618="Beta agonists in asthma: Acute administration and prophylactic use";
var content_f8_26_8618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beta agonists in asthma: Acute administration and prophylactic use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/26/8618/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8618/contributors\">",
"     Robert F Lemanske, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/26/8618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8618/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/26/8618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/26/8618/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/26/8618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta adrenergic drugs are the most potent bronchodilators currently available for clinical use in asthma and obstructive lung disease. Among the beta agonists, the individual agents vary in their rapidity of onset and duration of action. Inhaled, short-acting, selective beta-2 adrenergic agonists are the mainstay of acute asthma therapy, while inhaled, long-acting, selective beta-2 adrenergic agonists (in combination with inhaled glucocorticoids) play a role in long-term control of moderate to severe asthma.",
"   </p>",
"   <p>",
"    The mechanism of action of beta adrenergic medications and their clinical use in the management of asthma will be reviewed here. The general approach to asthma management, the treatment of acute exacerbations of asthma, and an overview of the delivery of inhaled medications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of acute exacerbations of asthma in adults\", section on 'Inhaled beta agonists'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta agonists were developed through modifications of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    molecule to allow selective interaction with the beta-1 and beta-2 receptors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ), rather than the combined alpha and beta effects of epinephrine. Further modification allows selectivity for beta-2 receptors on bronchial smooth muscle to achieve bronchodilation without the tachycardia associated with activation of beta-1 receptors on cardiac muscle. Agents that are selective for the beta-2 adrenergic receptor (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20372?source=see_link\">",
"     pirbuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ) are preferred for asthma therapy compared with nonbeta-2 selective agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"     metaproterenol",
"    </a>",
"    ), because they provide equivalent bronchodilation with less cardiac stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1\">",
"     1",
"    </a>",
"    ]. Isoproterenol, a nonselective beta agonist, is no longer used to treat asthma exacerbations, due to the better safety and duration of action profiles of other available medications.",
"   </p>",
"   <p>",
"    The beta-2 receptor is a G protein-coupled transmembrane receptor that activates the enzyme adenylyl cyclase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/2\">",
"     2",
"    </a>",
"    ]. Activation of adenylyl cyclase produces cyclic adenosine monophosphate (cAMP). The exact mechanism by which cAMP causes smooth muscle relaxation is not fully understood, but likely involves activation of protein kinase A and changes in intracellular calcium concentrations. Activation of the beta-2 receptor also affects potassium channels through a separate mechanism. The function of the beta-2 adrenergic receptor and the role of polymorphisms of the receptor in individual responses to beta agonists are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link\">",
"     \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variations in the molecular structure of beta agonists affect the onset and duration of bronchodilation. As an example, prolongation of the bronchodilator effect (relative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ) is achieved by modifications that reduce susceptibility to degradation by catechol O-methyl transferase (COMT) and monoamine oxidase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the long, lipophilic side chains of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    attach to the plasma membrane and increase the duration of binding of the drugs to the adrenergic receptor. The lipophilic side chain of salmeterol leads to incorporation of the drug into the cell membrane and activation of the beta adrenergic receptor through an alternate binding site, rather than the usual site in the aqueous surface of the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/2\">",
"     2",
"    </a>",
"    ]. It is thought that accessing the alternate binding site deeper in the cell membrane slows the onset of action of salmeterol. In contrast, formoterol has a different lipophilic side chain and its onset of action is comparable to that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    (also known as salbutamol).",
"   </p>",
"   <p>",
"    Chronic daily use of beta agonists to relieve symptoms may result in the paradoxical situation in which symptom control becomes progressively more difficult to achieve. One possible mechanism for this effect is down-regulation of the number of beta-2 adrenergic receptors on the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Tolerance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link&amp;anchor=H3#H3\">",
"     \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\", section on 'Receptor dysfunction in asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta-2 agonists also interact with beta adrenergic receptors on the surface of a variety of other cells that play a role in asthma pathogenesis. As examples, beta agonists have the potential to decrease mast cell mediator release, inhibit neutrophil, eosinophil, and lymphocyte functional responses, increase mucociliary transport, and affect vascular tone and edema formation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     USE IN ACUTE EXACERBATIONS OF ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting beta-2 agonists (SABAs) are the drug of choice for acute treatment of asthma symptoms and exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2109930\">",
"    <span class=\"h2\">",
"     Heterogeneity of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The individual response to beta agonist therapy for an acute exacerbation of asthma is related to many factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relative contribution of bronchoconstriction versus airway inflammation and edema in producing the underlying airway obstruction; bronchoconstriction is usually more responsive whereas the other components are not",
"     </li>",
"     <li>",
"      Route of medication delivery (oral, inhaled, parenteral) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Importance of route of delivery'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The triggering mechanism (exercise, allergen exposure, infection)",
"     </li>",
"     <li>",
"      Concurrent medication use and abuse (such as the extent of antecedent beta agonist use)",
"     </li>",
"     <li>",
"      Age, since airway geometry and the ability to utilize various delivery systems are important factors in children",
"     </li>",
"     <li>",
"      Duration of symptoms; a longer duration of symptoms (eg, days rather than minutes) typically suggests concomitant airway inflammation",
"     </li>",
"     <li>",
"      The outcome measure(s) used to evaluate the response, both subjective (eg, ease of breathing) and objective (eg, improvements in peak flow or spirometry)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with asthma exacerbations appear to require substantially higher doses of beta agonists to achieve reversal of bronchoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This relative resistance may reflect one of the above factors, or beta receptor downregulation due to the disease itself or to chronic beta agonist overuse [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, repetitive or continuous administration of a SABA is often needed for patients with moderate to severe exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/4\">",
"     4",
"    </a>",
"    ]. As the dose of SABA increases, the risk of toxicity and need for appropriate monitoring also increases (",
"    <a class=\"graphic graphic_table graphicRef68683 \" href=\"UTD.htm?4/34/4654\">",
"     table 1",
"    </a>",
"    ). The management of acute exacerbations of asthma is discussed separately. (See",
"    <a class=\"local\" href=\"#H179762302\">",
"     'Toxicity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of acute exacerbations of asthma in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Importance of route of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The route of delivery (eg, metered dose inhaler, nebulized, oral, subcutaneous, intravenous) of the beta agonist is another determinant of efficacy. It might be expected that oral or parenteral administration would be more effective than inhaled use, since mucous plugging might prevent adequate airway penetration of inhaled forms. However, studies evaluating the relative efficacy have shown that inhaled and subcutaneous routes are superior to oral therapy, but consensus as to whether the inhaled or subcutaneous route is superior has not been reached. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=see_link\">",
"     \"Delivery of inhaled medication in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=see_link\">",
"     \"Use of medication nebulizers in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link\">",
"     \"The use of inhaler devices in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients comment that the subjective clinical benefit observed following nebulized therapy is superior to that following metered dose inhalation; however, objective data using equal drug dosages generally do not support these claims [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. On the other hand, nebulizer therapy would be preferred for patients who are unable to cooperate effectively with use of a metered dose inhaler (MDI) because of their age, agitation, or severity of exacerbation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher doses of oral beta agonists are required to achieve a bronchodilator response comparable to inhaled preparations, due to poor absorption and rapid gastrointestinal metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1\">",
"       1",
"      </a>",
"      ]. Further, the therapeutic effect is delayed; peak bronchodilation does not occur until two hours after ingestion [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/9\">",
"       9",
"      </a>",
"      ], making oral administration appropriate only for mild to moderate asthmatic symptoms and perhaps in patients unable to use other delivery methods due to age or lack of immediate availability.",
"     </li>",
"     <li>",
"      Variable results have been obtained when inhaled and parenteral delivery routes are compared. In one study, for example, repeated inhalations of nebulized",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      (2.5 mg) produced more bronchodilation than subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      (0.3 mg) in acute asthma; each drug was given three times at 20 minute intervals [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/10\">",
"       10",
"      </a>",
"      ]. On the other hand, some patients who are initially refractory to a nebulized beta agonist may respond to subcutaneous epinephrine with peak flow rates increasing by 120",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      and both peak flow rates and FEV1 increasing by 20 percent or more above baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comparisons of nebulized or intravenous administration of individual beta-2 agonists have also been performed. While early evaluations suggested some advantages with intravenous administration [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/12\">",
"       12",
"      </a>",
"      ], subsequent studies with both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/13\">",
"       13",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/14\">",
"       14",
"      </a>",
"      ] have demonstrated equivalent or superior effects on pulmonary function with nebulized inhalation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/15\">",
"       15",
"      </a>",
"      ]. In a meta-analysis on the use of intravenous beta agonist therapy for acute asthma that compared the outcomes of 584 patients in 15 trials, intravenous therapy was not associated with improved outcomes in the study population or any identified subgroup [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/16\">",
"       16",
"      </a>",
"      ]. Intravenous administration of beta agonists is clearly associated with the development of more adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/13,14,17\">",
"       13,14,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Levalbuterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     Albuterol",
"    </a>",
"    is a racemic mixture with a 1:1 ratio of the isomers R-albuterol (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    ) and S-albuterol; the R-isomer is responsible for the drug's bronchodilating activity. The approval of the R-isomer of albuterol, levalbuterol, has led to controversy about whether it is superior to racemic albuterol as a bronchodilator in asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. While some investigators have concluded that levalbuterol has a better therapeutic ratio (fewer systemic effects for the same degree of bronchodilation) than albuterol [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/19,21-23\">",
"     19,21-23",
"    </a>",
"    ], others have not been able to support these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/24\">",
"     24",
"    </a>",
"    ]. Overall, levalbuterol appears to have no clinically significant advantage over racemic albuterol [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/18,25-28\">",
"     18,25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data in children treated in an emergency department setting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/24,29\">",
"     24,29",
"    </a>",
"    ] and in adults hospitalized with exacerbations of both asthma and COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/24,30\">",
"     24,30",
"    </a>",
"    ] have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    may reduce hospital admission rates (children) and reduce overall costs if the patient is hospitalized (adults). Conversely, other published results in children given levalbuterol in the emergency department setting do not support any advantage over racemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    in a number of outcome measures, including hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/27,31\">",
"     27,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is hypothesized that the S-isomer of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    activates pro-constrictive and pro-inflammatory pathways in bronchial smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/32\">",
"     32",
"    </a>",
"    ]. These effects would theoretically diminish the beneficial effects of the R-isomer (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    ), although the clinical importance of these detrimental effects is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until the results of additional comparison trials with racemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    have been published,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    use should be reserved for those patients who have a known history of adverse effects from albuterol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1487481\">",
"    <span class=\"h2\">",
"     Use as rescue medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting beta agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20372?source=see_link\">",
"     pirbuterol",
"    </a>",
"    ) in MDIs are the first line of therapy for the quick relief of acute asthma symptoms (eg, shortness of breath, cough, wheeze, chest tightness) (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/4,33\">",
"     4,33",
"    </a>",
"    ]. SABAs are prescribed for use as-needed, rather than on a routine basis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     Formoterol",
"    </a>",
"    , a long-acting beta agonist (LABA) has an acute onset of action in the same time frame as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, formoterol is not approved for quick relief of asthma symptoms due to insufficient data [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Escalating use of a SABA (&gt;6 to 8 puffs per day from a metered dose inhaler or use exceeding one canister per month) is a warning sign that the patient's underlying disease activity is inadequately controlled and that additional intervention is warranted (",
"    <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78322 \" href=\"UTD.htm?11/62/12269\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64986 \" href=\"UTD.htm?26/13/26845\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H27#H27\">",
"     \"An overview of asthma management\", section on 'Assessing control to adjust therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2109923\">",
"    <span class=\"h2\">",
"     Use in emergency department",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the response of patients with acute exacerbations of asthma to beta agonist therapy is not uniformly predictable. Nevertheless, a few initial guidelines can be proposed for asthmatic exacerbations severe enough to require presentation to the emergency department. Preparations of both inhaled and systemic beta-agonists, delivery systems, and dosing guidelines are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef68683 \" href=\"UTD.htm?4/34/4654\">",
"     table 1",
"    </a>",
"    ). The other aspects of treatment of asthma exacerbations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient can demonstrate proper metered dose inhaler (MDI) technique, two to six inhalations of a SABA (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      ) can be administered using a spacer or chamber device (eg, AeroChamber, InspirEase) (",
"      <a class=\"graphic graphic_picture graphicRef58957 \" href=\"UTD.htm?22/4/22607\">",
"       picture 1",
"      </a>",
"      ). Therapy can be repeated in 30 to 60 minutes until maximal improvement in pulmonary function can be demonstrated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"       \"The use of inhaler devices in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=see_link\">",
"       \"Delivery of inhaled medication in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alternatively, if the patient is unable to use the MDI, does not exhibit a satisfactory clinical response, or if the",
"      <span class=\"nowrap\">",
"       patient/providers",
"      </span>",
"      prefer nebulizer treatment, the SABA is administered by nebulizer. Doses of SABAs for nebulization are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef68683 \" href=\"UTD.htm?4/34/4654\">",
"       table 1",
"      </a>",
"      ). Within the range of doses, the higher doses and continuous nebulization are used for more severe exacerbations. However, the cumulative dose should be monitored because of the potential adverse effects, and should not exceed the recommended limits listed in the table. (See",
"      <a class=\"local\" href=\"#H2109930\">",
"       'Heterogeneity of response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H179762302\">",
"       'Toxicity'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link&amp;anchor=H10617078#H10617078\">",
"       \"Delivery of inhaled medication in adults\", section on 'Continuous nebulization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SABAs may be mixed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      for the initial management (first three hours) of severe exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of acute exacerbations of asthma in adults\", section on 'Inhaled anticholinergics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      (0.01",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to a maximum dose of 0.3 to 0.5 mg) is administered subcutaneously or intramuscularly, if nebulized therapy is either unavailable or ineffective clinically (",
"      <a class=\"graphic graphic_table graphicRef68683 \" href=\"UTD.htm?4/34/4654\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Intravenous beta agonist therapy, particularly with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      , is not recommended, since it has been associated with adverse cardiac effects [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1,17\">",
"       1,17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Importance of route of delivery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H179762302\">",
"       'Toxicity'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Beta agonist therapy is associated with a decrease in arterial oxygen tension (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) of 5 mmHg or more, so supplemental oxygen is provided to maintain the pulse oxygen saturation above 90 percent (above 95 percent in pregnant women and patients with coexistent cardiac disease), for severe exacerbations, or when continuous measurement of pulse oximetry is not available [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"       \"Pulse oximetry\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS IN ALLERGEN-INDUCED ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In IgE sensitized patients, relevant allergen exposure can elicit both an immediate (within minutes) bronchoconstrictive response and a late (hours) inflammatory response, which is often accompanied by recurrent bronchoconstriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are important differences in the ability of short and long-acting beta agonists to block these responses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short-acting beta agonists can attenuate the immediate response, but are generally ineffective in preventing or reversing the late response [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. SABAs do not substantially inhibit the inflammatory response.",
"     </li>",
"     <li>",
"      The long-acting beta agonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      , can block both the immediate and late phase bronchoconstrictive responses, but not the inflammatory response [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As pretreatment with a beta agonist does not block the initiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    propagation of airway inflammation by allergen or the resultant increase in bronchial hyperresponsiveness, allergen avoidance is always preferred over pretreatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .) Premedication with either cromolyn or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    sodium would likely prevent the airway inflammation associated with transient allergen exposure; however, the availability of these medications is limited (in the United States, cromolyn is only available in a nebulizer formulation) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link&amp;anchor=H2#H2\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\", section on 'Limitations on availability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     USE IN EXERCISE-INDUCED ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting beta agonists (SABAs) are considered to be the drug of choice for the prevention and treatment of exercise-induced bronchoconstriction (EIB) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179761390\">",
"    <span class=\"h2\">",
"     Proposed mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mechanisms have been proposed to explain how beta agonists inhibit EIB:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bronchodilation that they induce before exercise may counterbalance the asthma induced by exercise",
"     </li>",
"     <li>",
"      The normal bronchodilator response seen within the first few minutes of exercise may be enhanced, thereby overriding or attenuating the airway obstruction that follows exercise",
"     </li>",
"     <li>",
"      The mediator release associated with EIB may be inhibited due to activation of mast cell beta receptors",
"     </li>",
"     <li>",
"      The effect of beta agonists on smooth muscle may prevent mediator-induced bronchoconstriction",
"     </li>",
"     <li>",
"      Beta agonists may increase bronchial blood flow, which would reduce the heat loss in the airway that is thought to be one of the mechanisms of EIB [",
"      <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Efficacy of different preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of various beta agonists to inhibit or attenuate EIB is dependent upon the minute ventilation (work load) and the particular drug administered. Beta agonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"     metaproterenol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20372?source=see_link\">",
"     pirbuterol",
"    </a>",
"    attenuate EIB if taken ten minutes before exercise. The duration of protection varies with the agent used. Albuterol may attenuate EIB for four to six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/44\">",
"     44",
"    </a>",
"    ], whereas metaproterenol may only be protective for two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long acting beta agonists (LABAs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , are also very effective in attenuating EIA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Salmeterol needs to be used at least an hour before exercise, while formoterol can be used 5 to 10 minutes before. As one would expect, their duration of action is longer than the SABAs. As an example, the mean duration of a 50 percent reduction in EIB is 1.5 hours for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    versus 6.5 hours for formoterol [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/46\">",
"     46",
"    </a>",
"    ]. Inhaled salmeterol also prevents EIB and produces significant bronchodilation for at least 9 hours (",
"    <a class=\"graphic graphic_figure graphicRef73033 graphicRef81068 \" href=\"UTD.htm?25/8/25743\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the duration of protection induced by the long-acting preparations may decrease with chronic use (",
"    <a class=\"graphic graphic_figure graphicRef61821 \" href=\"UTD.htm?7/22/7534\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/48\">",
"     48",
"    </a>",
"    ]. Despite the more prolonged effect of LABAs and FDA approval for use in the prevention of EIB, we prefer not to use these agents as monotherapy for asthma or EIB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179761012\">",
"    <span class=\"h1\">",
"     LONG-TERM CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-acting beta agonists (LABAs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    , are used in combination with inhaled glucocorticoids for patients with moderate or severe asthma whose symptoms are inadequately controlled on inhaled glucocorticoid therapy alone, especially when nocturnal symptoms are problematic (",
"    <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57761 \" href=\"UTD.htm?2/45/2782\">",
"     table 7",
"    </a>",
"    ). LABAs have additive effects with inhaled glucocorticoids when the two agents are used in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. The use of LABAs to treat moderately severe and severe persistent asthma and the controversy regarding the safety of these medications for chronic maintenance therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link\">",
"     \"Treatment of severe asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LABAs should never be prescribed as monotherapy for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link&amp;anchor=H9#H9\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\", section on 'FDA advisory statement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TOLERANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased sensitivity or tolerance to beta agonists with chronic use has been identified in laboratory studies and is believed to be primarily mediated by downregulation of beta-2 adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/55\">",
"     55",
"    </a>",
"    ]. However, the clinical importance of this effect is unclear. Most investigators believe that the duration of action of the bronchodilator response is affected more than the peak effect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1\">",
"     1",
"    </a>",
"    ], and that oral routes are more likely to induce tolerance than inhaled methods of delivery. Beta-2 adrenergic receptor polymorphisms appear to influence this effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link&amp;anchor=H4#H4\">",
"     \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\", section on 'Receptor polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the laboratory, the development of tolerance requires relatively continuous stimulation of the membrane-associated beta receptors. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    would theoretically be more likely to produce tolerance than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    , which has a shorter duration of action [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/56\">",
"     56",
"    </a>",
"    ]. However, two randomized trials of the safety and efficacy of albuterol administered on a regular schedule compared to an as-needed regimen in patients with mild asthma failed to demonstrate evidence of tolerance to the acute bronchodilating properties of this beta agonist or an increase in the rate of exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the expectation that longer duration of action (and thus more continuous stimulation of the beta receptors) would increase the development of tolerance, LABAs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ) would be more likely to induce tolerance than shorter acting agents. However, clinical studies have yielded mixed results. One study found that twelve weeks of regular therapy with salmeterol did not result in a diminution in bronchodilating efficacy or a change in the use of rescue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    therapy (",
"    <a class=\"graphic graphic_figure graphicRef78242 \" href=\"UTD.htm?37/25/38302\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/59\">",
"     59",
"    </a>",
"    ]. In contrast, some decrease in the ability of salmeterol to protect against a bronchoconstrictive stimulus has been observed in other reports following a similar duration of salmeterol therapy (",
"    <a class=\"graphic graphic_figure graphicRef61821 \" href=\"UTD.htm?7/22/7534\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/48,60,61\">",
"     48,60,61",
"    </a>",
"    ]. Chronic use of formoterol has also been shown to reduce the acute bronchodilator response to albuterol following methacholine-induced bronchoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to a potential problem with tolerance, chronic reliance on beta agonist inhalers may disadvantage patients whose disease process involves mechanisms other than bronchial smooth muscle constriction. Without proper recognition and intervention, patients may use more SABA inhalations at progressively more frequent intervals to obtain symptom relief. This overuse has the disadvantages of delaying addition of other therapeutic agents (such as anti-inflammatory drugs) that can reverse or attenuate other important pathophysiologic factors, such as airway edema, mucus secretion, and inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179762302\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta agonists are associated with several side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/63\">",
"     63",
"    </a>",
"    ]. Tremor is the most frequent acute side effect and is more noticeable with oral therapy than with inhaled agents. Patient acceptance of tremor is often related to diminished awareness of the tremor due to decreased peak-trough variations over time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/1,64\">",
"     1,64",
"    </a>",
"    ]. Increased heart rate and palpitations are dose-dependent and are less common with the selective beta-2 agonists (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) than with nonselective agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"     metaproterenol",
"    </a>",
"    ). Use of a spacer or chamber device reduces these side effects by reducing oral deposition of medication, which contributes to side effects but not bronchodilation.",
"   </p>",
"   <p>",
"    Stress-induced (takotsubo) cardiomyopathy has been associated with treatment of status asthmaticus in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link&amp;anchor=H3#H3\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\", section on 'Physical or emotional stress'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metabolic disturbances, such as hyperglycemia and hypokalemia, are also reported, although the clinical significance is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. In some patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    may reduce the incidence of these side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/26/8618/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H17666854#H17666854\">",
"     \"Causes of hypokalemia\", section on 'Elevated beta-adrenergic activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"       \"Patient information: Asthma in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"       \"Patient information: Asthma in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=see_link\">",
"       \"Patient information: Medicines for asthma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=see_link\">",
"       \"Patient information: Inhalers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=see_link\">",
"       \"Patient information: How to use your metered dose inhaler (adults) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7232106\">",
"    <span class=\"h2\">",
"     Acute exacerbations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta adrenergic agonists are the most potent and rapidly acting bronchodilator medications available for asthma treatment. Beta agonists interact with beta adrenergic receptors on a variety of cells to relax bronchial smooth muscle, decrease mast cell mediator release, inhibit neutrophil, eosinophil, and lymphocyte functional responses, increase mucociliary transport, and affect vascular tone and edema formation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary use of short acting beta agonists (SABAs) is the quick relief of acute asthma symptoms (eg, shortness of breath, cough, wheeze, chest tightness). SABAs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"       levalbuterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20372?source=see_link\">",
"       pirbuterol",
"      </a>",
"      ) are prescribed for use as-needed, rather than on a routine basis. Acute exacerbations of asthma are heterogeneous and the response to therapy is not uniformly predictable. Inhaled and systemic beta-agonist preparations, delivery systems, and dosing guidelines are listed in the tables (",
"      <a class=\"graphic graphic_table graphicRef72467 \" href=\"UTD.htm?15/34/15917\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68683 \" href=\"UTD.htm?4/34/4654\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Use in acute exacerbations of asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled SABAs (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ) remain the drug of choice for asthma exacerbations requiring emergency department treatment. Those who can demonstrate proper MDI technique are initially treated with two to six inhalations of a SABA administered from an MDI using a spacer or chamber device (eg, AeroChamber, InspirEase) (",
"      <a class=\"graphic graphic_picture graphicRef58957 \" href=\"UTD.htm?22/4/22607\">",
"       picture 1",
"      </a>",
"      ). Alternatively, albuterol is administered by nebulizer (",
"      <a class=\"graphic graphic_table graphicRef68683 \" href=\"UTD.htm?4/34/4654\">",
"       table 1",
"      </a>",
"      ). SABA MDI or nebulizer therapy can be repeated in 30 to 60 minutes until maximal improvement in pulmonary function can be demonstrated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Use in acute exacerbations of asthma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of acute exacerbations of asthma in adults\", section on 'Inhaled beta agonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of acute asthma exacerbations, including severity assessment, monitoring, use of other medications, and disposition, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"       \"Treatment of acute exacerbations of asthma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If a satisfactory clinical response to MDI administration of a SABA is not achieved or if the exacerbation is severe, a SABA is administered by nebulizer, either as individual treatments every 20 minutes or as a continuous treatment (eg, for more severe exacerbations); the doses are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef68683 \" href=\"UTD.htm?4/34/4654\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2109923\">",
"       'Use in emergency department'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link&amp;anchor=H10617078#H10617078\">",
"       \"Delivery of inhaled medication in adults\", section on 'Continuous nebulization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rarely,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      (0.01",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      to a maximum dose of 0.3 mg) is administered subcutaneously or intramuscularly to treat acute asthma exacerbations and is reserved for times when nebulized therapy is either unavailable or ineffective clinically. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Use in acute exacerbations of asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Until the results of additional comparison trials with racemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      have been published,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"       levalbuterol",
"      </a>",
"      use should be reserved for those patients who have a known history of adverse effects from albuterol. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Levalbuterol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7232095\">",
"    <span class=\"h2\">",
"     Prevention of exacerbations and long-term control",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the ability of beta agonists to prevent or attenuate allergen-induced bronchoconstriction, avoidance of allergen exposure by sensitized patients is always preferred over pretreatment with a SABA. Pretreatment does not block the airway inflammation and resultant increase in bronchial hyperresponsiveness associated with allergen exposure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prophylaxis in allergen-induced asthma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"       \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short-acting beta agonists (SABAs) are considered to be the drug of choice for the prevention and treatment of exercise-induced bronchoconstriction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Use in exercise-induced asthma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link&amp;anchor=H10#H10\">",
"       \"Exercise-induced bronchoconstriction\", section on 'Pharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long acting beta agonists (LABAs) are used in combination with inhaled glucocorticoids for patients with moderate or severe asthma whose symptoms are inadequately controlled with inhaled glucocorticoid therapy. LABAs should never be prescribed as monotherapy. The controversy regarding long-term use of beta agonists is discussed separately. (See",
"      <a class=\"local\" href=\"#H179761012\">",
"       'Long-term control'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"       \"Beta agonists in asthma: Controversy regarding chronic use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7232126\">",
"    <span class=\"h2\">",
"     Tolerance and toxicity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased sensitivity or tolerance to beta agonists is a potential effect that may occur with chronic, continuous use of beta agonists. The effect appears primarily mediated by downregulation of beta-2 adrenergic receptors, such that increasing agonist doses are required for the same degree of bronchodilation. The clinical significance of tolerance largely relates to patients who overuse beta agonist inhalers, rather than appropriately avoiding the relevant exposure (eg, allergen) or adding appropriate anti-inflammatory controller medication. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Tolerance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potential role of adrenergic receptor polymorphisms in development of tolerance is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=see_link&amp;anchor=H4#H4\">",
"       \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\", section on 'Receptor polymorphisms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tremor is the most frequent acute side effect associated with beta agonists. Other side effects include palpitations, tachycardia, metabolic disturbances, and rarely stress-induced (takotsubo) cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H179762302\">",
"       'Toxicity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"       \"Stress-induced (takotsubo) cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sorkness CA. Beta-adrenergic Agonists. In: Middleton's Allergy: Principles and Practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, Philadelphia 2009. p.1485-503.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/2\">",
"      Johnson M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatr Respir Rev 2001; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/3\">",
"      Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117:18.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/5\">",
"      Tipton WR, Nelson HS. Frequent parenteral terbutaline in the treatment of status asthmaticus in children. Ann Allergy 1987; 58:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/6\">",
"      Schuh S, Parkin P, Rajan A, et al. High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics 1989; 83:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/7\">",
"      Colacone A, Afilalo M, Wolkove N, Kreisman H. A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. Chest 1993; 104:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/8\">",
"      Idris AH, McDermott MF, Raucci JC, et al. Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest 1993; 103:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/9\">",
"      Wolfe JD, Yamate M, Biedermann AA, Chu TJ. Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics. JAMA 1985; 253:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/10\">",
"      Fanta CH, Rossing TH, McFadden ER Jr. Treatment of acute asthma. Is combination therapy with sympathomimetics and methylxanthines indicated? Am J Med 1986; 80:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/11\">",
"      Appel D, Karpel JP, Sherman M. Epinephrine improves expiratory flow rates in patients with asthma who do not respond to inhaled metaproterenol sulfate. J Allergy Clin Immunol 1989; 84:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/12\">",
"      Williams S, Seaton A. Intravenous or inhaled salbutamol in severe acute asthma? Thorax 1977; 32:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/13\">",
"      Pierce RJ, Payne CR, Williams SJ, et al. Comparison of intravenous and inhaled terbutaline in the treatment of asthma. Chest 1981; 79:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/14\">",
"      Salmeron S, Brochard L, Mal H, et al. Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study. Am J Respir Crit Care Med 1994; 149:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/15\">",
"      Travers AH, Rowe BH, Barker S, et al. The effectiveness of IV beta-agonists in treating patients with acute asthma in the emergency department: a meta-analysis. Chest 2002; 122:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/16\">",
"      Travers A, Jones AP, Kelly K, et al. Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database Syst Rev 2001; :CD002988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/17\">",
"      Maguire JF, O'Rourke PP, Colan SD, et al. Cardiotoxicity during treatment of severe childhood asthma. Pediatrics 1991; 88:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/18\">",
"      Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001; 108:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/19\">",
"      Gawchik SM, Saccar CL, Noonan M, et al. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999; 103:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/20\">",
"      \"Pharmaceutical Approvals Monthly\" FDC Reports. Chevy Chase, MD. 2005; 10(3):11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/21\">",
"      Handley DA, Tinkelman D, Noonan M, et al. Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 2000; 37:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/22\">",
"      Tripp K, McVicar WK, Nair P, et al. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. J Allergy Clin Immunol 2008; 122:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/23\">",
"      Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998; 102:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/24\">",
"      L&ouml;tvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001; 108:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/25\">",
"      Levalbuterol for asthma. Med Lett Drugs Ther 1999; 41:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/26\">",
"      Datta D, Vitale A, Lahiri B, ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest 2003; 124:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/27\">",
"      Qureshi F, Zaritsky A, Welch C, et al. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005; 46:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/28\">",
"      Hamilos DL, D'Urzo A, Levy RJ, et al. Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma. Ann Allergy Asthma Immunol 2007; 99:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/29\">",
"      Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003; 143:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/30\">",
"      Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003; 123:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/31\">",
"      Hardasmalani MD, DeBari V, Bithoney WG, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005; 21:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/32\">",
"      Agrawal DK, Ariyarathna K, Kelbe PW. (S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol 2004; 113:503.",
"     </a>",
"    </li>",
"    <li>",
"     Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. www.ginasthma.org (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/34\">",
"      Grembiale RD, Pelaia G, Naty S, et al. Comparison of the bronchodilating effects of inhaled formoterol, salmeterol and salbutamol in asthmatic patients. Pulm Pharmacol Ther 2002; 15:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/35\">",
"      Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/36\">",
"      Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987; 79:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/37\">",
"      Howarth PH, Durham SR, Lee TH, et al. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985; 132:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/38\">",
"      Twentyman OP, Finnerty JP, Harris A, et al. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/39\">",
"      Bundgaard A, Buch D, Schmidt A, Bach-Mortensen N. Pretreatment of exercise-induced asthma in children using disodium cromoglycate and fenoterol inhalation powder. Eur J Respir Dis Suppl 1983; 130:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/40\">",
"      Rohr AS, Siegel SC, Katz RM, et al. A comparison of inhaled albuterol and cromolyn in the prophylaxis of exercise-induced bronchospasm. Ann Allergy 1987; 59:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/41\">",
"      Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. J Allergy Clin Immunol 1989; 83:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/42\">",
"      McFadden ER Jr. Hypothesis: exercise-induced asthma as a vascular phenomenon. Lancet 1990; 335:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/43\">",
"      Anderson SD, Daviskas E. The airway microvasculature and exercise induced asthma. Thorax 1992; 47:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/44\">",
"      Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/45\">",
"      Sly RM, Heimlich EM, Ginsburg J, et al. Exercise-induced bronchospasm: evaluation of metaproterenol. Ann Allergy 1968; 26:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/46\">",
"      Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992; 89:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/47\">",
"      Green CP, Price JF. Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Arch Dis Child 1992; 67:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/48\">",
"      Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/49\">",
"      Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; :CD005533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/50\">",
"      Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005; :CD005535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/51\">",
"      O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/52\">",
"      Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/53\">",
"      Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/54\">",
"      Lemanske RF Jr, Busse WW. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol 2010; 126:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/55\">",
"      Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 1990; 4:2881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/56\">",
"      Repsher LH, Anderson JA, Bush RK, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest 1984; 85:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/57\">",
"      Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/58\">",
"      Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/59\">",
"      Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/60\">",
"      Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/61\">",
"      Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/62\">",
"      Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 2005; 99:566.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson HS. Beta-adrenergic agonists. In: Middleton's Allergy: Principles and Practice, 6th Ed, Adkinson NF, Yunginger JW, Busse WW, et al (Eds), Mosby, St Louis 2003. p.803.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/64\">",
"      Jenne JW, Valcarenghi G, Druz WS, et al. Comparison of tremor responses to orally administered albuterol and terbutaline. Am Rev Respir Dis 1986; 134:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/65\">",
"      Kurisu S, Inoue I, Kawagoe T, et al. Assessment of medications in patients with tako-tsubo cardiomyopathy. Int J Cardiol 2009; 134:e120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/66\">",
"      Osuorji I, Williams C, Hessney J, et al. Acute stress cardiomyopathy following treatment of status asthmaticus. South Med J 2009; 102:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/67\">",
"      Rennyson SL, Parker JM, Symanski JD, Littmann L. Recurrent, severe, and rapidly reversible apical ballooning syndrome in status asthmaticus. Heart Lung 2010; 39:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/68\">",
"      Leslie D, Coats PM. Salbutamol-induced diabetic ketoacidosis. Br Med J 1977; 2:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/69\">",
"      van den Berg BT, Louwerse RT, Luiken GJ, et al. Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol. Clin Drug Investig 1998; 15:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/70\">",
"      Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 97:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/26/8618/abstract/71\">",
"      Guhan AR, Cooper S, Oborne J, et al. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55:650.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 558 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8618=[""].join("\n");
var outline_f8_26_8618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      USE IN ACUTE EXACERBATIONS OF ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2109930\">",
"      Heterogeneity of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Importance of route of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Levalbuterol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1487481\">",
"      Use as rescue medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2109923\">",
"      Use in emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROPHYLAXIS IN ALLERGEN-INDUCED ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      USE IN EXERCISE-INDUCED ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179761390\">",
"      Proposed mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Efficacy of different preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179761012\">",
"      LONG-TERM CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TOLERANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179762302\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7232106\">",
"      Acute exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7232095\">",
"      Prevention of exacerbations and long-term control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7232126\">",
"      Tolerance and toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/558\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/558|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/16/9486\" title=\"figure 1A\">",
"      Long acting beta agonist in EIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/29/4574\" title=\"figure 1B\">",
"      Beta agonist effect in EIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/22/7534\" title=\"figure 2\">",
"      Attenuation of beta agonist effect in EIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/25/38302\" title=\"figure 3\">",
"      Persistence of beta agonist effect over time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/558|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/4/22607\" title=\"picture 1\">",
"      MDI spacers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/558|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/34/4654\" title=\"table 1\">",
"      Doses of beta agonists for asthma exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/34/15917\" title=\"table 2\">",
"      Doses beta agonist preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/33/39453\" title=\"table 3\">",
"      Adjusting Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/62/12269\" title=\"table 4\">",
"      Adjusting Rx 0 to 4 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/13/26845\" title=\"table 5\">",
"      Adjusting Rx 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/48/38668\" title=\"table 6\">",
"      Usual doses inhaled GC-LABA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/45/2782\" title=\"table 7\">",
"      Doses asthma control meds kids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15239?source=related_link\">",
"      Beta-2 adrenergic receptor dysfunction and polymorphism in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31014?source=related_link\">",
"      Delivery of inhaled medication in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=related_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/34/41506?source=related_link\">",
"      Patient information: How to use your metered dose inhaler (adults) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/43/30386?source=related_link\">",
"      Patient information: Inhalers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30376?source=related_link\">",
"      Use of medication nebulizers in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_26_8619="Histology gallbladder cancer";
var content_f8_26_8619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common histologic types of gallbladder cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tumor type*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenocarcinoma",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papillary",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucinous",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenosquamous",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oat cell",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonspecified",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Data collected from 3, 038 patients treated between 1977 and 1986. Two-year survival for papillary type was 47 percent. For tumors limited to the gallbladder, five-year survival was 32 percent.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Henson, DE. Cancer 1992; 70:713.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8619=[""].join("\n");
var outline_f8_26_8619=null;
var title_f8_26_8620="Different Starlings forces";
var content_f8_26_8620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Starling's forces in different organs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Skeletal muscle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alveoli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Hydraulic pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Capillary (mean)",
"       </td>",
"       <td class=\"centered\">",
"        17.3",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interstitium",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;3",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mean gradient",
"       </td>",
"       <td class=\"centered\">",
"        20.3",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Oncotic pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Capillary (mean)",
"       </td>",
"       <td class=\"centered\">",
"        28",
"       </td>",
"       <td class=\"centered\">",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interstitium",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mean gradient",
"       </td>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Net gradient favoring filtration",
"       </td>",
"       <td class=\"centered\">",
"        0.3",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Approximate values for Starling's forces in skeletal muscle and alveoli. Units are mmHg. The mean capillary oncotic pressure rises in the glomerulus because of the filtration of relatively protein-free fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Guyton AC. Chapter 16. In: Textbook of Medical Physiology, 8th ed, Saunders, Philadelphia 1991.",
"      </li>",
"      <li>",
"       Taylor AE. Circ Res 1981; 49:557.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8620=[""].join("\n");
var outline_f8_26_8620=null;
var title_f8_26_8621="Promotion of language literacy";
var content_f8_26_8621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggestions for enhancing a child's language and literacy skills before kindergarten entry",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Parents are encouraged to provide repeated experiences in development of the following areas:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Expressive and receptive language readiness skills:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Understand and express the following linguistic concepts:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Quality: Show me the one that is the same. Show me the one that is different.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Quantity: Which coat has more/fewer/the most buttons?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       Position words:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Put the book on the lower shelf.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Show me the boy farthest from the tree.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       Show me the boy nearest to the tree.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       (Other positions are in front of, behind, ahead of, first, last, etc.)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Direction words: Take the doll up the ladder. Take the doll down the ladder.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Time words: Before I clap my hands, stand up.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Verb tense, passive: Show me: The truck was hit by the car.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Identify the sound patterns of words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Rhyming words",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Rhyming sentences",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Nursery rhymes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3_start\">",
"       Alliteration: Sister Suzie is sitting by the seashore sifting sand...",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       What is the common sound?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Understand and re-tell narrative stories",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Reading readiness skills",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Recognize the meaning of common signs and symbols in the environment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sing the ABC song",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Develop an awareness of print",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Show me the title.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Show me where I should begin reading.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       What story do the pictures tell?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Show me where the story ends.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Show me how to turn the pages.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Writing readiness skills",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hold a pencil or crayon with an appropriate grasp",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Assemble multi-piece wooden and cardboard puzzles of people, animals, forms, numbers, or letters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Create models of airplanes, prehistoric animals, cars, etc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Use crayons or a pencil to draw, follow the dots, or solve maze tasks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Copy patterns using beads on a string, a pegboard, or parquetry blocks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Use wooden or plastic blocks to match geometric shapes and build copies of models",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Find shapes or designs in a picture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Copy geometric configurations with rubber bands stretched between rows of nails on a board",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted in part from recommendations compiled by staff members of the Learning Support Center, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8621=[""].join("\n");
var outline_f8_26_8621=null;
var title_f8_26_8622="Rhinovirus infection";
var content_f8_26_8622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Proposed sequence of events during rhinovirus infection of nasal epithelium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 239px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8622=[""].join("\n");
var outline_f8_26_8622=null;
var title_f8_26_8623="EHL for entrapped basket";
var content_f8_26_8623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrohydraulic lithotripsy of a common bile duct stone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopic view demonstrating a basket containing a gallstone (red arrow), which has become entrapped in the bile duct. A daughter scope has been advanced into the bile duct (green arrow) permitting fragmentation of the stone using electrohydraulic lithotripsy (EHL). Following EHL, both the basket and the stone were removed and the bile duct cleared of stones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Isaac Raijman, MD and Susana Escalante, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_26_8623=[""].join("\n");
var outline_f8_26_8623=null;
